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  V 
Riassunto 
 
 
 
 
L’attività di ricerca che ho svolto riguarda lo studio di nuovi composti a potenziale azione 
antineoplastica sintetizzati dal gruppo del prof. Cirrincione presso l’Università di Palermo. 
Sono state valutate 104 molecole dotate di attività antiproliferativa, sia come tali sia in seguito ad 
attivazione con luce UVA (fotochemioterapici); in particolare, ho studiato due serie di 
pirrolochinazoline (BQ e LCQ) ed una serie di pirazolochinoline (PZQ). 
Per tutti questi composti sono stati effettuati esperimenti di citotossicità in vitro volti a confermare 
la loro azione citotossica e/o fotocitotossica; alcune di queste molecole hanno dimostrato una 
discreta attività antiproliferativa, anche nell’ordine del sub-micromolare, mentre altre sono risultate 
inattive alle concentrazioni utilizzate. 
Per i derivati più attivi sono poi stati effettuati ulteriori test citofluorimetrici per determinare il 
meccanismo di morte cellulare. Come risultato, queste sostanze sembrano indurre morte cellulare 
attraverso apoptosi, fenomeno che coinvolge alcuni organelli quali mitocondri e lisosomi; in 
particolare, sono state riscontrate variazioni del potenziale di membrana mitocondriale e produzione 
di specie reattive dell’ossigeno (ROS), fattori che indicano un importante coinvolgimento dei 
mitocondri. I lisosomi, invece, sembrano essere coinvolti nel fenomeno apoptotico solo in un 
secondo momento. 
Per la serie BQ, poi, sono stati effettuati test volti a determinare il meccanismo d’azione. 
Inizialmente è stata valutata l’inibizione dell’EGFR, visto che questi composti erano stati 
sintetizzati allo scopo di ottenere degli inibitori di questo recettore tirosinchinasico; dai risultati 
ottenuti, tuttavia, questo non sembra essere il meccanismo d’azione della serie. 
Dal momento che questi composti inducono un blocco nelle fasi G2/M del ciclo cellulare, ho allora 
valutato una potenziale azione antimitotica; attraverso l’analisi dell’indice mitotico, della rete dei 
microtubuli e della polimerizzazione della tubulina in vitro questa ipotesi è stata confermata. 
Spesso, inoltre, gli antimitotici possiedono un’azione antivascolare che, in questo caso, è stata 
valutata mediante alcuni test preliminari in vitro; il trattamento con le pirrolochinazoline più attive 
sembra inibire la motilità cellulare e danneggiare la rete capillare neoformata da cellule HUVEC. 
Per quel che riguarda, infine, i composti fotocitotossici, sono stati valutati i potenziali danni a carico 
di proteine e lipidi.  
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Abstract 
 
 
 
 
My research activity is based on the study of new potential anticancer compounds synthesised at 
Palermo University by prof. Cirrincione’s group. 
In this study, 104 new cytotoxic molecules were evaluated in the presence of UVA photoactivation 
or in the dark; particularly, some pyrroloquinazolines (BQ and LCQ series) and some 
pyrazoloquinolines (PZQ series) were assessed. 
Cytotoxicity and photocytotoxicity assays were performed in vitro to confirm the antiproliferative 
activity of these derivatives; some molecules showed an interesting cytotoxicity, even in the sub-
micromolar range, others were inactive at the employed concentrations. 
The most cytotoxic compounds among these series were then further analysed by flow cytometric 
assays to find cell death mechanism. These molecules induce cell death by apoptosis with the 
involvement of mitochondria and lysosomes; particularly, the mitochondrial membrane potential 
and the production of reactive oxygen species (ROS) were tested: this is indicative of an important 
involvement of mitochondria. Instead, lysosomes are involved later compared to mitochondria. 
Furthermore, the most active BQ derivatives were investigated to find out their mechanism of 
action. At first, because of their structural analogy with some EGFR inhibitors, these compounds 
were tested for this mechanism of action; nevertheless, they do not seem to be EGFR inhibitors. 
Since these derivatives provoke a block in G2-M phase in cell cycle, I evaluated their potential 
antimitotic activity; this hypothesis was confirmed by further studies as mitotic index, microtubule 
network perturbation and tubulin polymerisation in vitro. 
Many antimitotic drugs can also have an effect on tumour immature and neo-formed vessel 
network, and this feature was assessed by some preliminary tests in vitro; the most active 
pyrroloquinazolines showed to inhibit cell motility and disrupt a neo-formed HUVEC vessel 
network. 
Finally, a possible damage against lipids and proteins induced by the most photocytotoxic 
compounds was evaluated. 
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1. Introduction 
 
 
 
 
In the developed world, roughly one in three people contracts cancer and around one in four of 
those dies from the disease [1]. 
Over the period 1980–2000, total cancer mortality for men was 166/100 000 in the EU, including 
lung and other tobacco-related neoplasms, but also stomach, intestines and liver, and a few 
neoplasms such as testis, Hodgkin’s disease and leukaemias. Overall cancer mortality for women 
was 95/100 000 in the EU. 
Most of the unfavourable patterns and trends in cancer mortality are due to recognised, and hence 
largely avoidable, causes of cancer. These include the exceedingly high rates of lung and other 
tobacco-related cancers but also the high rates of gastric and intestinal cancer, related to poorer and 
unfavourable dietary patterns. Alcohol drinking is also responsible for the gross excess and the 
consequent unfavourable trends in oral cavity, oesophageal and laryngeal cancers. The elevated 
liver cancer rates were largely due to high hepatitis B and C prevalence. Furthermore, there are high 
mortality rates for neoplasms related to inadequate screening, diagnosis and treatment, mainly for 
uterine cervical cancer, with the lack of adoption of effective screening programs, but also for 
breast and ovarian cancers, as well as testicular cancer, Hodgkin’s disease and leukaemias [2]. 
Advances in treatment, with surgery, radiotherapy and conventional cytotoxic chemotherapy, have 
made only a modest overall impact on mortality. Cures can be achieved in childhood cancers, 
testicular cancer and lymphoma, and improvements in survival rates have been made as a result of 
adjuvant drug treatment of breast and colorectal cancer. However, the majority of human cancers is 
difficult to treat, especially in their advanced, metastatic forms. There is thus a pressing need for 
novel and effective forms of systemic therapy [3]. 
 
 
 
1.1 The hallmarks of cancer 
 
In cancer, the particular challenge is to discover the series of molecular abnormalities that arise in 
the genomes of all types of cancer in precise detail, to use that information to understand the 
Introduction 
________________________________________________________________________________ 
 2 
process of malignancy, and then to develop more rational and effective strategies for diagnosis and 
treatment. 
Complex cellular functions are generated by the dynamic interactions of a large number of 
molecular components (DNA, RNA, proteins and small molecules) modulated by internal and 
external cues. Thus the function is not determined by a single component or a single level of 
organization, but is found distributed as an emergent (or system-level) property over many levels 
and components. Accordingly, a cell can be viewed as a system composed of many interconnected 
modules coordinately performing specific biological functions (metabolism, signalling, 
transcription, growth, cycle, autophagy, apoptosis, differentiation, etc.), each module being 
characterized by a network of interacting molecules [4]. 
Tumourigenesis in humans is a multistep process; these steps reflect genetic alterations that drive 
the progressive transformation of normal human cells into highly malignant derivatives.  
Cancer cells have defects in regulatory circuits that govern normal cell proliferation and 
homeostasis. The vast catalogue of cancer cell genotypes is a manifestation of six essential 
alterations in cell physiology that collectively dictate malignant growth. 
- Self-sufficiency in growth signals: tumour cells show a greatly reduced dependence on 
exogenous growth stimulation and they generate many of their own growth signals, thereby 
reducing their dependence on stimulation from their normal tissue microenvironment. 
- Insensitivity to growth-inhibitory (antigrowth) signals: within a normal tissue, multiple 
antiproliferative signals operate to maintain cellular quiescence and tissue homeostasis; 
incipient cancer cells must evade these antiproliferative signals if they are to prosper. 
- Evasion of programmed cell death (apoptosis): the ability of tumour cell population to 
expand in number is determined not only by the rate of cell proliferation, but also by the rate 
of cell attrition; programmed cell death represents a major source of this attrition and 
acquired resistance toward apoptosis is a hallmark of most and perhaps all types of cancer. 
- Limitless replicative potential: three acquired capabilities – growth signal autonomy, 
insensitivity to antigrowth signals, and resistance to apoptosis – all lead to an uncoupling of 
a cellular growth program from signals in its environment. In principle, the resulting 
deregulated proliferation program should suffice to enable the generation of the vast cell 
populations that constitute macroscopic tumours; however, research performed over the past 
30 years indicates that this acquired disruption of cell-to-cell signalling, on its own, does not 
ensure expansive tumour growth. 
- Sustained angiogenesis: the oxygen and nutrients supplied by the vasculature are crucial for 
cell function and survival, obligating virtually all cells in a tissue to reside within 100 µm of 
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a capillary blood vessel. During organogenesis, this closeness is ensured by coordinated 
growth of vessels and parenchyma. The cells within aberrant proliferative lesions initially 
lack angiogenic ability, curtailing their capability for expansion. In order to progress to a 
larger size, incipient neoplasias must develop angiogenic ability. 
- Tissue invasion and metastasis: sooner or later during the development of most types of 
human cancer, primary tumour masses spawn pioneer cells that move out, invade adjacent 
tissues, and thence travel to distant sites where they may succeed in founding new colonies; 
these distant settlements of tumour cells – metastases – are the cause of 90% of human 
cancer deaths. The capability for invasion and metastasis enables cancer cells to escape the 
primary tumour mass and colonize new terrain in the body where, at least initially, nutrients 
and space are not limiting. The newly formed metastases arise as amalgams of cancer cells 
and normal supporting cells conscripted from the host tissue. Successful invasion and 
metastasis depend upon all of the other five acquired hallmark capabilities. 
Each of these physiologic changes – novel capabilities acquired during tumour development – 
represents the successful breaching of an anticancer defence mechanism hardwired into cells and 
tissues [5]. 
 
 
 
1.2 Chemotherapy 
 
The word “chemotherapy” was created by Herlich at the beginning of the 20th century and it meant 
a medical therapy which uses synthetic chemical compounds as antimicrobials [6]. Now, this word 
indicates drugs for anticancer therapy with the aim of slowing or blocking neoplastic cellular 
proliferation through cytotoxic mechanisms. 
The success possibility for a chemotherapeutic agent is as greater as the differences between target 
cells and healthy ones. If these differences are few, as in the case of a neoplastic cellular population 
and the original healthy cellular population, an anticancer agent cannot eliminate tumour cells 
without giving toxic effects to the patient. In fact, tissues or organs with a high proliferative index, 
such as bone marrow, epithelia of the gastro-intestinal tract and skin, are chemotherapy target like 
cancerous cells; this unwanted damage causes hair loss, nausea, infections and much other side 
effects. 
Moreover, the efficacy of all chemotherapeutic agents is limited by the occurrence of drug 
resistance [7]. Multidrug resistance (MDR) is characterized clinically as a broad cross-resistance to 
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chemotherapeutic drugs and is the main reason for the failure of chemotherapy. Whereas MDR is 
inherently expressed in some cancers, in others it develops in response to treatment. Overexpression 
of the mdr1 gene product, P-glycoprotein, produces an MDR phenotype characterised by decreased 
accumulation of drug and cross-resistance to lipophilic natural-product drugs. P-glycoprotein is 
primarily located in the plasma membrane of drug-resistant cells, and it is believed that the 
decreased drug accumulation is the result of the adenosine triphosphate (ATP)-dependent drug-
effluxing activity of P-glycoprotein. Similarly, increased expression of the MDR-associated protein 
(MRP) causes resistance to a range of lipophilic natural product drugs. 
The molecular mechanism of MRP-mediated resistance has not yet been clearly defined. It is 
thought that MRP acts similarly to P-glycoprotein and causes drug efflux since MRP has several 
features in common with P-glycoprotein, such as its sequence homology with mdr1, its location 
primarily in the plasma membrane and its association with decreased intracellular drug 
accumulation [8]. 
 
 
1.2.1 Chemotherapeutics and cell cycle 
 
Chemotherapeutics are antiproliferative agents, so there is often a connection between cell cycle 
and cytotoxicity. The cell cycle is commonly deregulated in cancer. This frequently occurs in a 
variety of ways at the level of cyclin-dependent kinases (CDKs) and their regulatory molecules [3]. 
 
 
Fig. 1.1 Cell cycle phases. 
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Cell cycle can be divided into four phases: 
- G1 phase, in which the synthesis of enzymes for the functioning and production of new 
DNA occurs. 
- S phase, with the synthesis of DNA and the duplication of genome. 
- G2 phase, associated with the metabolic activity for the production of all needed components 
for mitosis. 
- M phase (mitosis), marked by the generation of bipolar mitotic spindles, the segregation of 
sister chromatids and cell division. 
There are also cells in G0 phase or in quiescence state. External stimuli (mitogens or growth factors) 
induce them to move out of G0 and through the early part of G1 [9]. These external stimuli are 
communicated through a cascade of intracellular phosphorylations, by upregulating expression of 
the cyclins, which associate with the CDKs. 
Anticancer drugs can be divided into three categories considering their relationship with cell cycle: 
- Cycle non-specific, which demonstrate their antiproliferative activity independently of the 
presence of cells in cycle, that is also for cells in G0 phase; 
- Phase-specific, which kill cells when they are in a specific phase of the cycle; 
- Phase non-specific, which are active towards proliferating cells but independently of cell 
cycle phase. 
This classification is important for the operative meaning. For example, in a big tumour mass, there 
are often a lot of quiescent cells and so the therapeutic approach should begin with radiotherapy, 
surgery but also with the use of cycle non-specific drugs [10]. 
 
 
1.2.2 Classification of chemotherapeutic agents 
 
Chemotherapeutic agents can be classified by their different mechanism of action: 
• Antimetabolites: these drugs prevent the reproduction of tumour cells altering metabolic 
pathway such as the synthesis of folate, purines, pyrimidines and nucleosides, and so the 
synthesis of nucleic acids. These compounds present similar structures to endogenous 
metabolites, and this structural analogy causes the block of an enzymatic system or the 
synthesis of an inactive product. In this group, we can find methotrexate, which inhibits the 
formation of tetrahydrofolic acid, a coenzyme of DNA synthesis, acting as an anti-folic; 
purine analogues, such as 6-mercaptopurine or 6-thioguanine, which are able not only to 
inhibit purine synthesis but also to incorporate into DNA or RNA, damaging them; 
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pyrimidine analogues, such as ara-c, which inhibits DNA-polymerase, or 5-fluorouracile, 
which blocks DNA synthesis through the binding to timidilate synthetase and, when 
incorporated into RNA, causes errors during transcription [11]. Antimetabolites are phase-
specific drugs as they inhibit DNA synthesis during S phase [10]. 
• Alkylators: they show the ability to alkylate nucleophilic sites in cellular macromolecules. 
Although these agents damage virtually all components of the cell, their biological effects 
are attributable to their direct interaction with DNA through the formation of a covalent 
bond between the activated form of the drug (electrophilic carbocation) and the nucleophilic 
nitrogen bases. Alkylating agents react with DNA either directly or via intermediaries, 
which are formed by metabolic activation or spontaneous chemical degradation [12]. 
Damage to base residues can result in further chemical modifications such as loss of a base 
and interstrand or intrastrand DNA crosslinking. Nitrogen mustards, nitrosoureas, 
mitomycins, tetrazines, platinum coordination complex belong to this group of drugs. 
Alkylators are cytotoxic in cells independently of cell cycle and so also in quiescent cells; 
however, they are more efficacious towards highly proliferating tissues, in which G1 and S 
phases are very vulnerable. After DNA alkylation, cells accumulate and die in G2 phase 
[10]. 
• Topoisomerase inhibitors: topoisomerases are enzymes that can change the topological state 
of DNA through the breaking and rejoining of DNA strands. Cells encode two classes of 
topoisomerases that are distinguished by their catalytic mechanisms. Type I topoisomerases 
act by generating a transient single-stranded break in the double helix, followed by either a 
single-stranded DNA passage event or controlled rotation about the break. As a result, these 
enzymes are able to alleviate torsional stress (i.e., remove superhelical twists) in duplex 
DNA [13]. Type II topoisomerases act by generating a transient double-stranded DNA 
break, followed by a double-stranded DNA passage event. Consequently, these enzymes are 
able to remove superhelical twists from DNA and resolve knotted or tangled duplex 
molecules [14]. Topoisomerases are valuable targets for cancer chemotherapeutic agents. 
Several classes of topo inhibitors have been introduced into cancer clinics as potent 
anticancer drugs, including camptothecins (Irinotecan, Topotecan) inhibiting topo I and 
anthracyclines (Doxorubicin, Daunorubicin), epipodophyllotoxins (etoposide, teniposide), 
aminoacridines (amsacrine) and ellipticines, targeting topo II. The activity of these agents is 
thought to derive from stabilization of DNA/topo cleavable complex, an intermediate in the 
catalytic cycle of the enzymes, resulting ultimately in apoptosis. As cells in S and G2 phase 
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present the highest levels of topoisomerase, inhibitors are more cytotoxic during these 
phases [10]. 
• Antimitotic agents: these agents interfere with microtubules, which are essential components 
of the cytoskeleton that help regulate diverse processes such as cell migration, cell growth, 
organelle transport and correct segregation of chromosomes during mitosis [15]. 
Microtubule system is a high dynamic structure, constantly growing and shortening, and 
antimitotic drugs affect this dynamics by interacting with tubulin. The most clinically useful 
classes of antimitotic drugs are the Vinca alkaloids and the taxanes [16]. The strategy of 
using tubulin as a target for cancer chemotherapy is based on the increased growth and 
division of cancer cells and the fact that drugs that interfere with mitosis such as the Vinca 
alkaloids, which shift the equilibrium to the depolymerised form of tubulin, have proven 
effective in the treatment of cancer. Taxanes target tubulin but, unlike the Vinca alkaloids 
and colchicine, shift the equilibrium to the polymerized form, thus stabilizing microtubules. 
Antimitotic agents prevent the normal formation and above all the dynamics of mitotic 
spindle, stopping cellular division in metaphase. Nevertheless, as microtubules take part in 
many cellular functions (intracellular transport, signal transduction, receptor mechanisms), 
antimitotic agents can damage cells not only in mitosis but also during interphase [17]. 
• Hormones or their antagonists: tumours originated by hormone-sensitive tissues can retain 
their hormone-dependency, which can be used for the inhibition of their growth. Hormones 
with opposite activity to the ones that induce tumour development or hormone antagonists 
can be used. For example antiestrogens, such as tamoxifene, or antiandrogens, such as 
cyproterone, can be implied for hormone-dependent breast or prostate carcinoma, 
respectively [10]. 
A new generation of cancer drugs (‘targeted therapy’) was designed to interfere with a specific 
molecular target (typically a protein) that is believed to have a critical role in tumour growth or 
progression. The identification of appropriate targets is based on a detailed understanding of the 
molecular changes underlying cancer [18]. This approach presents some advantages, such as the 
reduction of side effects thanks to the improvement of tumour specificity and the choice of the 
therapy after the identification of the molecular target alteration in the specific neoplasm. Among 
these new drugs, we can find inhibitors of kinases, which have so far proved to be a promising class 
of targets for cancer therapy. Kinases play key roles in cancer as they are directly or indirectly 
involved in most signalling pathway. 
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Fig. 1.2 EGFR pathway. 
 
All these enzymes make use of ATP for phosphorylation of a specific Ser/Thr/Tyr residue on 
protein substrates. The success of small-molecule ATP-competitive inhibitors, such as imatinib 
(Gleevec) for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal 
tumours (GIST), and gefitinib (Iressa) and erlotinib (Tarceva) for the treatment of non-small-cell 
lung cancer (NSCLC), confirms that this strategy is indeed effective [19]. However, classical 
chemotherapy and radiotherapy approaches remain the mainstay of cancer treatment for tumours 
that cannot be cured solely by surgical excision. For example these conventional cancer therapies 
may be combined with targeted agents that disrupt the DNA-repair response; hopefully a more 
catastrophic cell kill in tumours will result [18]. 
 
 
 
1.3 Cell death mechanisms 
 
Cell death occurs frequently in complex, multicellular organisms to maintain tissue homeostasis. 
For example, cells die during embryonic development. Also, the killing of infected cells by 
cytolytic effector cells of the immune system is an example of cell death in tissue maintenance. 
Cell death is discriminated into two main forms: apoptosis and necrosis. In contrast to necrosis, 
apoptosis is a regulated, energy-dependent form of cell death leading to phagocytosis of cellular 
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remnants by neighbouring cells. Characteristic morphological features of these two forms of cell 
death will be discussed and correlated to underlying molecular mechanisms [20]. 
 
 
Fig. 1.3 Apoptosis and necrosis. 
 
 
1.3.1 Necrosis 
 
The term necrosis is used for a type of cell death that is not programmed but rather accidental. In 
contrast to apoptosis, necrosis is a passive form of cell death without the intricate regulatory 
mechanisms that are characteristic of apoptosis. 
The causes of necrotic cell death, such as heat stress or toxic agents, can also induce apoptotic cell 
death in many cases. The intensity of the insult but also the energy level of a cell often decide the 
outcome as either apoptosis or necrosis. It could be shown that low ATP concentration or impaired 
ATP generation pushes the morphology of cell death toward necrosis. 
The morphology of cells dying by necrosis is fairly diverse. The cell membrane becomes permeable 
early during the death process. Organelles may dilate, and ribosomes may dissociate from the 
endoplasmic reticulum. The nucleus disintegrates later, and in some cases chromatin condensation 
occurs. However, pyknotic and fragmented nuclei are not a common feature in necrotic cell death. 
Due to early leakage of cellular contents, a massive inflammation in the tissue is triggered. 
Depending on the morphology and the involvement of lysosomes, two different types of necrotic 
cell death have been distinguished: autophagic and nonlysosomal disintegration. The autophagic 
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cell death is characterized by numerous vacuoles in the cytoplasm filled with cellular remnants. The 
nonlysosomal cell death shows that a pronounced dilation of organelles and empty spaces are 
formed and the degeneration proceeds without any detectable involvement of lysosomes [20]. 
 
 
1.3.2 Apoptosis 
 
The ability of tumour cell populations to expand in number is determined not only by the rate of cell 
proliferation but also by the rate of cell attrition. Programmed cell death – apoptosis – represents a 
major source of this attrition and acquired resistance towards apoptosis is a hallmark of many types 
of cancer. The possibility that apoptosis serves as a barrier to cancer was first raised in 1972, when 
Kerr, Wyllie, and Currie described massive apoptosis in the cells populating rapidly growing, 
hormone-dependent tumours following hormone withdrawal. 
The apoptotic program is present in latent form in virtually all cell types throughout the body. Once 
triggered by a variety of physiologic signals, this program unfolds in a precisely choreographed 
series of steps. Cellular membranes are disrupted, the cytoplasmic and nuclear skeletons are broken 
down, the cytosol is extruded, the chromosomes are degraded, and the nucleus is fragmented, all in 
a span of 30–120 min. In the end, the shrivelled cell corpse is engulfed by nearby cells in a tissue 
and disappears, typically within 24 hr. 
The apoptotic machinery can be broadly divided into two classes of components – sensors and 
effectors. The sensors are responsible for monitoring the extracellular and intracellular environment 
for conditions of normality or abnormality that influence whether a cell should live or die. These 
signals regulate the second class of components, which function as effectors of apoptotic death. The 
sentinels include cell surface receptors that bind survival or death factors. Intracellular sensors 
monitor the cellular well-being and activate the death pathway after detecting abnormalities, 
including DNA damage, signalling imbalance provoked by oncogene action, survival factor 
insufficiency, or hypoxia. Further, the life of most cells is in part maintained by cell–matrix and 
cell–cell adherence-based survival signals whose abrogation elicits apoptosis [5]. 
One of the earliest signals of apoptosis is the externalisation of phosphatidylserine, providing an 
“eat-me” signal for phagocytosing cells. This can be employed in vitro as marker for the detection 
of apoptosis. 
Morphological hallmarks of apoptosis in the nucleus are chromatin condensation and nuclear 
fragmentation. The condensation starts peripherally along the nuclear membrane, forming a 
crescent or ring-like structure. During later stages of apoptosis the nucleus further condenses, and 
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finally it breaks up inside a cell with an intact cell membrane. These morphological features can be 
initiated by the cleavage of various proteins by caspases. A major hallmark of apoptosis in the 
nucleus is the internucleosomal fragmentation of double-stranded DNA into fragments of 180- to 
200-bp length. A number of caspase substrates that are involved in DNA repair and replication is 
responsible for this fragmentation of DNA. 
Early during the initiation of apoptosis, cells lose contact with neighbouring cells. Membranes and 
organelles including mitochondria are well preserved during early apoptotic cell death. 
Subsequently, microvilli are lost and the cells start to show protrusions of the plasma membrane 
commonly referred to as blebs. The cells shrink, and finally the blebs separate, forming apoptotic 
bodies densely packed with cellular organelles and nuclear fragments that are engulfed by 
phagocytosis of surrounding cells [20]. 
The ultimate effectors of apoptosis include an array of intracellular proteases termed caspases. Two 
“gatekeeper” caspases, -8 and -9, are activated by death receptors such as FAS or by the 
cytochrome c released from mitochondria, respectively. These proximal caspases trigger the 
activation of effector caspases that execute the death program through selective destruction of 
subcellular structures and organelles, and of the genome [5]. 
The activation of caspase proteases is fundamental to apoptotic cell death, although their mode of 
action in promoting death is not fully understood. In vertebrate cells, inhibition of caspases does not 
necessarily prevent cell death but profoundly delays and alters the process [21]. 
Apoptosis occurs without associated inflammation due to the containment of the cellular 
constituents by an intact membrane and the subsequent engulfment of apoptotic bodies. However, if 
the remnants of apoptotic cells are not phagocytised, they will undergo degradation that resembles 
necrosis and is called secondary necrosis [20]. 
 
1.3.2.1 Mitochondria role in apoptosis 
 
Mitochondria are semi-autonomous organelles that change in shape, size and association in 
different tissues or physio- pathological conditions. Morphological, biochemical, and genetic 
mitochondrial dysfunction has been reported to occur in several cancer cells. 
Mitochondria play a key role in cellular bioenergetics, ion homeostasis, carbohydrate, and fatty 
acids metabolism and cell signalling. They are at the centre of several inter-connected important 
metabolic pathways, which are further connected to other important cellular functions. 
Consequently, any local mitochondrial dysfunction can potentially have direct or indirect effects on 
intra or extra mitochondrial metabolic pathways [4]. 
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During apoptosis, mitochondria suffer specific damages that result in the loss of their function. For 
example, release of cytochrome c, the sole water soluble component of the electron transfer chain, 
can potentially halt the electron transfer, leading to failure in maintaining the mitochondrial 
membrane potential and ATP synthesis. Moreover, because cytochrome c carries electrons from 
cytochrome c reductase (complex III) to cytochrome c oxidase (complex IV), by which oxygen 
molecules are reduced to water, a blockade at this step would increase the production of reactive 
oxygen species with subsequent lipid peroxidation [21]. 
The central role of mitochondria in the process of apoptosis has been a focus of cell death research 
since the observations that the antiapoptotic Bcl-2 protein localizes to the outer membrane of this 
organelle, a mitochondria-rich fraction is required for the induction of apoptotic changes in a cell-
free system, and mitochondrial transmembrane potential is lost during an early stage of apoptosis 
[22]. 
Members of the Bcl-2 family of proteins, which have either proapoptotic (Bax, Bak, Bid, Bim) or 
antiapoptotic (Bcl-2, Bcl-XL, Bcl-W) function, act in part by governing mitochondrial death 
signalling through cytochrome c release [5]. 
Over the past several years, it has become clear that a major event during apoptosis is the 
permeabilization of the mitochondrial outer membrane to release proteins from the intermembrane 
space. Several of these, including cytochrome c, AIF, Smac/DIABLO, Omi/Htra2, and EndoG, 
have roles in subsequent cell death. In particular, the release of cytochrome c induces the activation 
of caspase proteases through the induction of apoptosome formation. 
Mitochondrial functions including protein import, ATP generation, and lipid biogenesis depend on 
the maintenance of transmembrane potential, and loss of transmembrane potential during apoptosis 
is likely to contribute to the death of the cell through loss of these functions. In addition, 
mitochondrial production of reactive oxygen species (ROS) also appears to play a role in cell death.  
The relationships between these events, release of mitochondrial proteins, and caspase activation 
remain controversial. This rapid effect of caspases on the function of the electron transport chain is 
therefore likely to be a major contributing factor to the process of caspase-dependent cell death 
[22]. 
 
1.3.2.2 Lysosomes role in apoptosis 
 
Under oxidative stress, iron-catalysed oxidation within the lysosomal compartment leads to 
lysosomal leak and rupture. Minor lysosomal destabilization of this sort will trigger reparative 
autophagocytosis and restoration of normal cellular function. However, more marked lysosomal 
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leakage and rupture are associated with apoptotic and, in extremis, necrotic cell death. Interestingly, 
early and minor lysosomal leak induced by oxidative stress will cause further lysosomal 
destabilization and, ultimately, apoptosis, which occurs long after removal of the oxidant stress. 
The intimate involvement of lysosomal leakage in apoptosis is emphasized by the finding that the 
release of mitochondrial cytochrome c can occur secondary to this lysosomal destabilization. 
Therefore, the release of lysosomal hydrolytic enzymes into the cytosol may be a key event, leading 
to proteolytic activation of pro-caspases and/or other cytosolic lytic pro-enzymes. 
These early events then might lead to further lysosomal destabilization and direct attack on 
mitochondria, with consequent cytochrome c release. This scenario would be consistent with the 
aforementioned progressive lysosomal rupture occurring long after removal of the oxidant stress. 
Bcl-2 might somehow act to interrupt this sequence of events: Bcl-2 over-expression effectively 
prevents the later lysosomal destabilization and, expectably, apoptosis. These findings raise the 
possibility that Bcl-2 somehow blocks downstream events that result in the later phase of lysosomal 
rupture, and that this activity may be involved in the still mysterious mode of action of this anti-
apoptotic protein [23]. 
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1.4 Photomedicine 
 
Photomedicine is employed to cure various cutaneous and neoplastic diseases and includes 
phototherapy and photochemotherapy [24]. Phototherapy and photochemotherapy are treatments in 
which the light with an appropriate wavelength is used to induce a therapeutic response, in the 
absence or in presence of a photosensitizer drug, respectively. To be effective, light has to be 
adsorbed by an endogenous chromophore (phototherapy) or by a photosensitizer agent 
(photochemotherapy), which can be administered by topical or systemic way. 
The electromagnetic spectrum can be divided into subgroups on the basis of the biological effects of 
each wavelength. We limit our discussion to radiation within the ultraviolet range (10-400 nm). 
 
 
Fig. 1.4 Electromagnetic spectrum. 
 
Ultraviolet radiation (UVR) can be divided into several subtypes, which are, from shortest to 
longest wavelengths, UVC (200-290 nm), UVB (290-320 nm), and UVA (320-400 nm). UVA can 
be further divided into UVA2 (320-340 nm) and UVA1 (340-400 nm). 
Broadband (BB) UVB was one of the first phototherapy modalities used in the treatment of 
psoriasis. Today, however, the more commonly used form of UVB is narrowband (NB) UVB, 
which has a peak emission at 311 nm. A series of clinical trials have demonstrated its superiority in 
the treatment of psoriasis and other conditions when compared with BB UVB. Today, it has become 
a first-line therapy in the treatment of psoriasis and other nonpsoriatic conditions because of its 
many advantages. In addition, NB UVB treatment may be home or office based. 
Unlike UVB radiation, UVA has the ability to penetrate to the deep dermis and subcutis. UVA1, 
because of its proximity to visible light on the far end of the UVA spectrum, does not induce 
erythema effectively, whereas UVA2, which resides at the lower wavelengths of UVA, may be 
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associated with effects similar to UVB, including acute sunburn. The therapeutic potential of UVA1 
first emerged in 1992 in the treatment of atopic dermatitis and then in 1995 for the treatment of 
localized scleroderma. UVA1 has been reported to have efficacy in a growing number of skin 
disorders. 
UV radiation exerts a multitude of biological effects in the skin from mutagenic to immunologic 
ones. The depth of penetration of the different light sources used for medical therapy dictates in 
which part of the skin they exert their greatest effect. UVB has more energy than UVA, but has less 
capability to penetrate beyond the superficial layers of the skin. Thus, UVB primarily affects 
Langerhans cells and epidermal keratinocytes. UVA radiation, particularly UVA1, reaches the deep 
dermis and potentially the subcutis, thereby impacting dermal fibroblasts, dendritic cells, 
lymphocytes, mast cells, and granulocytes. 
The ability to induce lymphocyte apoptosis is an important immunomodulatory effect of UVA and 
UVB phototherapy. T cells are highly susceptible to the effects of UV irradiation. 
The apoptotic effect of UVB is modulated via multiple mechanisms, including the Fas/Fas ligand 
system, p53, and apoptotic proteases. The apoptotic effects of UVA1 are different from those 
associated with UVB and include 2 independent caspase systems and an immediate apoptotic effect 
that may target specific types of cells preferentially [25]. 
Photochemotherapy can be divided into two main types: photodynamic therapy (PDT) and PUVA 
therapy. 
PDT is a rapidly growing modality for the treatment of light-accessible tumours [26]. It involves 
two individually non-toxic components that are combined to induce cellular and tissue effects in an 
oxygen-dependent manner. The first component of PDT is photosensitizer – a porphyrine derivative 
that localizes to a target cell and/or tissue. The second component involves the administration of 
visible light that activate the sensitizer. The photosensitizer transfers energy from light to molecular 
oxygen to generate singlet oxygen. 
PUVA therapy combines the effects of Psoralens and UVA light [27]. Oral administration of 
psoralens followed by irradiation of the cutaneous area by UVA radiation has been successfully 
used for the treatment of numerous autoimmune and/or hyperproliferative skin diseases, such as 
psoriasis, mycosis fungoides, lichen planus and vitiligo [28]. The most common PUVA regimen in 
the United States uses 8-methoxypsoralen (8-MOP), which is administered orally 2 hours before 
UVA irradiation. Bath PUVA is application of a topical psoralen before UVA irradiation, either to 
the entire body or limited areas (hands and feet). Advantages of bath PUVA include shorter 
irradiation times and a lack of gastrointestinal side effects associated with oral psoralens, but its use 
is limited by need for special facilities, patient inconvenience, and unpredictability (although this is 
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minimal for localized topical PUVA). Consequently, PUVA is usually administered via the use of 
oral psoralen [25]. 
 
 
1.4.1 Psoralens and PUVA therapy 
 
Psoralens are planar, tricyclic compounds, consisting of a furan ring fused to a coumarin moiety. 
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Fig. 1.5 Furocoumarins. 
 
Most psoralens have strong absorption bands in the range 200–350 nm, with lower absorbance 
towards the visible region of the spectrum. 
After the absorption of a photon by a molecule in the ground state, an electron is promoted to an 
excited singlet state. From here, it may return to the ground state, by the emission of a photon 
(fluorescence), or by the release of energy in the form of heat (radiationless collisional 
deactivation). Relatively infrequently, the electron in the singlet state can undergo intersystem 
crossing to the triplet state. Until there is some interaction with another molecule – be it another 
psoralen molecule, or more interestingly, something like DNA – all of the foregoing processes 
represent reversible photophysical processes. The excited state forms of the molecule can undergo 
several different photoreactions: photoaddition, photodimerization and/or photo-oxidation of nearby 
moieties (components of nucleic acids, proteins, membranes). Alternatively, energy transfer from 
the triplet state to molecular oxygen (normally in the triplet ground state) can lead to highly reactive 
singlet oxygen. Electron transfer from the sensitised molecule to a target molecule, leading to 
radical formation, is a type I photodynamic reaction. 
The photochemical reactions of psoralens with DNA are the best characterized, having been studied 
for nearly 40 years. Their planar aromatic structure and hydrophobic nature facilitate their 
intercalation with DNA bases. Upon photoactivation of the intercalated psoralen molecule, different 
adducts may be formed: in particular a [2+2]-photocycloaddition can occur between one of the 
photoreactive sites in the psoralen moiety (i.e. the double bonds in 3,4 of the pyrone ring and in 
4’,5’ of furan ring) and a double bond in a DNA base. From in vitro DNA photochemistry it has 
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been shown that the most frequently occurring adducts are those with thymine, followed by 
cytosine–psoralen adducts (10–20 times less efficiently). A psoralen–adenine photoadduct has also 
been characterized after in vitro photoreactions with adenine, but it has not yet been shown to occur 
in DNA isolated from cells irradiated in the presence of psoralens. The crosslinking process 
depends on the structure of the psoralen. Linear furocoumarins form crosslinks efficiently (up to 
50% of total adducts formed). Angular furocoumarins, or angelicins, were long thought to be unable 
to form crosslinks because of their geometry. Thus, the extent and nature of adduct-formation and 
the distribution between monoadducts and crosslinks depend on the psoralen derivative, the nucleic 
acid sequence of the DNA and the dose and wavelength of radiation used for photoactivation. 
Although DNA psoralen photochemistry has attracted the most attention, psoralens also react with 
proteins as well as other cell constituents. In studies of the subcellular fractions of rat epidermis 
after treatment with 8-MOP and UVA, it was found that 17% of the 8-MOP was bound to DNA, 
while a substantial amount was bound to proteins (57%) and lipids (26%). Several studies have 
demonstrated the ability of 8-MOP and TMP to react in an oxygen-independent way with 
unsaturated fatty acids. Proteins and lipids appear to form adducts with the pyrone ring in 8-MOP 
whereas DNA reacts with the furan moiety [29]. 
The combination of 8-methoxypsoralen and UVA irradiation is widely used for the treatment of 
various disorders mediated by T-cell (T-cell lymphomas, psoriasis). Special application of PUVA 
has been developed and named extracorporeal therapy according to its practical performance. 
Mononuclear cells (2–5% total volume of peripheral blood) are withdrawn from the patient’s blood, 
submitted to UVA-activated 8-MOP and finally returned into the body. 
A special immunomodulation response to this therapy is being developed in the organism and it is 
based on T-cell apoptosis and monocyte activation. UVA excitation of  8- MOP can lead to reactive 
oxygen species production playing an important role in oxidative damage of DNA, proteins and 
unsaturated lipids [30]. Although 8-MOP is biologically inert in the absence of UVA, the 
combination of 8-MOP and UVA causes the formation of monoadducts and covalent crosslinks of 
DNA [31]. Planar structure of 8-MOP enables its intercalation into double strand space of DNA. 
Following UVA-activation the 8-MOP molecule binds covalently to thymines of the opposite DNA 
strands and forms cross-links which hamper DNA replication. This results in decreased cell 
proliferation and cell death by apoptosis. 
Apoptosis induction by PUVA treatment has been described in a number of experimental systems. 
However, the apoptosis is only triggered if the alteration is irreparable. If it is not the case the G2/M 
checkpoint prevents cells from entering mitosis until the damage is repaired [30]. 
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1.4.1.1 Side effects and contraindications of PUVA 
 
Patients treated with UVA1 most commonly report no side effects other than tanning and, less 
commonly, erythema and pruritus. UVA1 has been reported to cause a polymorphic light eruption 
and activation of herpes simplex infection [25]. 
Nevertheless, PUVA therapy shows various toxic effects, such as severe skin erythema, and 
genotoxicity, with induction of point mutations and chromosomal aberrations. In addition, PUVA 
therapy is associated to a certain risk of skin cancer. Various authors attributed these dangerous 
effects to the severe damage induced into DNA by furocoumarin sensitisation. In fact psoralens 
form covalent monoadducts with pyrimidine bases, or diadducts: covalent inter-strands cross-links 
with two pyrimidine bases on the opposite DNA strands, and covalent DNA-protein cross-links 
[32]. The side effects of the psoralen, 8-MOP, used in PUVA therapy, include nausea and 
gastrointestinal upset. One strategy for reducing the side effects of 8-MOP–induced nausea is to 
decrease the dose and compensate by increasing the dose of UVA by the same percentage. 8-MOP 
may also be substituted with 5-MOP, which is relatively equivalent in efficacy and produces fewer 
side effects. 
As mentioned previously, bath PUVA carries some inconveniences as compared with oral psoralen 
therapy. Despite these inconveniences, bath PUVA is preferential in patients with limited treatment 
areas, such as the hands and feet, and may also be considered in patients who would otherwise have 
difficulty in tolerating oral psoralen (when facilities are available). In addition, some patients 
treated with PUVA complain of a painful, burning itch that may persist for months after treatment. 
Currently, PUVA is the only phototherapeutic modality definitively linked with the development of 
melanoma and nonmelanoma skin cancer in white patients. Various factors modulate the risk of 
carcinogenesis in each patient before any exposure to phototherapy. These factors include 
Fitzpatrick skin type, preexisting actinic damage, age, and personal habits and behaviour (extensive 
outdoor exposure, tanning bed use). These elevate the baseline risk for carcinogenesis for each 
patient and therefore, additional exposure to further risk is clearly contraindicated [25]. 
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2. Aim of the project 
 
 
 
 
This project is focused on studying new antiproliferative compounds synthesized by prof. 
Cirrincione’s group in the Department of Molecular and Biomolecular Sciences and Technologies 
at Palermo University. Particularly, three series of compounds were analysed: 
• BQ series 
• LCQ series 
• PZQ series 
For every compound at first chemical and physical properties were analysed and then its 
antiproliferative activity in many cell lines was evaluated; the most active molecules, moreover, 
were further investigated. 
 
 
 
2.1 BQ and LCQ series 
 
These compounds were synthesized to identify new potential inhibitors of tyrosine kinase activity. 
Receptor tyrosine kinases (RTKs) have been shown to be important mediators of signal 
transduction in cells. These transmembrane molecules characteristically consist of an extracellular 
ligand-binding domain connected through a segment in the plasma membrane to an intracellular 
tyrosine kinase domain. Binding of the ligand to the receptor results in receptor dimerization and 
stimulation of the receptor-associated tyrosine kinase activity, which leads to phosphorylation of 
tyrosine residues on both the receptor and other intracellular molecules. These changes in tyrosine 
phosphorylation initiate a signalling cascade leading to a variety of cellular responses [33]. 
RTKs, particularly, are associated to various growth factor receptors, for example EGFR 
(Epidermal Growth Factor Receptor), VEGFR (Vascular Endothelial Growth Factor Receptor) and 
PDGFR (Platelet Derived Growth Factor Receptor). 
The epidermal growth factor receptor is known to be overexpressed in a large percentage of clinical 
cancers of various types and to be associated with poor prognosis. Compounds which inhibit the 
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ability of EGFR to transmit a phosphorylation signal following binding of EGF are therefore of 
potential interest as anticancer drugs [34]. 
VEGF is an important stimulator of both normal and pathological angiogenesis. VEGF has been 
shown to be secreted by human tumour cell lines in culture (e.g. glioma and melanoma). Moreover, 
VEGF protein as well as mRNA for the VEGF receptors Flk-1/KDR have been identified in 
primary tumours of breast, colon, and renal origin. Blockade of VEGF signal transduction has been 
shown to prevent tumour growth. VEGF RTKs must, therefore, be viewed as attractive therapeutic 
targets for the development of novel agents to treat angioproliferative diseases such as cancer [33]. 
Platelet derived growth factor (PDGF) is known to act as a potent mitogen and chemotactic factor 
for various cells such as fibroblasts, smooth muscle cells, mesenchymal cells, and brain glial cells. 
Abnormal PDGF-induced cell proliferation has been proposed to lead to proliferative disorders such 
as atherosclerosis, restenosis following percutaneous transluminal coronary angioplasty, 
glomerulonephritis, glomerulosclerosis, liver cirrhosis, pulmonary fibrosis, and cancer. 
Additionally, PDGF and its receptor (PDGFR) are also upregulated in these proliferative disorders. 
Therefore, an inhibitor of PDGFR phosphorylation would be expected to possess a therapeutic 
potential in the treatment of these proliferative disorders [35]. 
In the past decade, efforts aimed at the discovery of therapeutically useful inhibitors of protein 
kinases have intensified. These efforts have resulted in the identification of a variety of templates 
which, depending upon the nature of attached substituents, provide selective inhibition both within 
and across different protein kinase families. One of these privileged scaffolds is the quinazoline 
nucleus, which has served as the core template for a variety of ATP-competitive kinase inhibitors. 
The leading examples of reversible quinazoline-based inhibitors are the clinically approved 
anticancer agents gefitinib (Iressa) and erlotinib (Tarceva). Both compounds are inhibitors of the 
receptor tyrosine kinase activity of the epidermal growth factor receptor (EGFR/HER1). There are 
also quinazoline-based compounds which target both EGFR and the related RTK HER2, for 
example the reversible inhibitor lapatinib or the irreversible inhibitor afatinib, which is undergoing 
clinical trials. Outside of the HER family, clinical compounds based on the quinazoline scaffold 
which target vascular endothelial growth factor receptor-2 (VEGFR-2/KDR) have been approved. 
Additionally, there are reports of other quinazoline-based RTK inhibitors, including compounds 
which target the tyrosine kinase activity of the platelet-derived growth factor receptor (PDGFR). 
The search for novel analogues of the quinazoline template has generated kinase inhibitors 
containing a variety of carbon-fused heterocycles [36]; prof. Cirrincione’s group synthesized these 
news compounds through the condensation of the quinazoline structure to a pyrrolic group: pyrrolo, 
in fact, is also present in some tyrosine kinase inhibitors [34,36]. 
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The BQ series is composed by 49 pyrrolo[3,4-h]quinazoline derivatives: 
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This series has been widely explored. After the evaluation of spectroscopic properties, cytotoxicity 
was determined on various tumoral cell lines; the most active molecules were then analysed with 
regard to cell death mechanism, cell cycle studies and mechanism of action. 
The LCQ compounds are 17 pyrrolo[2,3-h]quinazoline derivatives: 
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These compounds have shown to be less active than BQ derivatives, so photocytotoxicity was 
tested with remarkable results: these molecules, in fact, are heteroanalogues of angelicin, so they 
were investigated as photoactivable agents. The most active compounds were afterwards analysed 
with flow cytometry assays and tested to identify their potential target. 
 
 
 
2.2 PZQ series 
 
PZQ series is composed by 38 pyrazolo[3,4-h]quinolines, synthesized as angelicin analogues with 
photochemotherapeutic activity. 
PUVA has been used for more than 2 decades as a very effective therapeutic modality for various 
diseases such as psoriasis, chronic eczema, cutaneous T-cell lymphoma and other primary and 
secondary lymphoproliferative disorders, and cutaneous graft-versus-host disease after allogeneic 
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stem cell transplantation [37]. The combination of psoralens and UV-light controls excess cell 
division in the skin by its ability to damage DNA. The lesions in DNA lead to inhibition of DNA 
synthesis, skin pigmentation and erythema production. On the other hand, psoralens show 
mutagenic and carcinogenic effects [38]. Much effort has gone into finding more active compounds 
with diminished side effects. In PZQ derivatives the oxygen atom at position 1 of angelicin has 
been substituted with a nitrogen atom and the furan ring with a pyrazole ring; furthermore, C3 has 
been replaced by a phenylsulphonyl or an ethoxycarbonyl group and the nitrogen atom at position 7 
has been substituted in most cases by a group with remarkable steric hindrance. 
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First of all, spectroscopic and photochemical features have been determined for these compounds; 
successively, cytotoxicity and photocytotoxicity were evaluated on tumour and non-tumour cell 
lines, with and without scavengers. The most active molecules were then further analysed to 
establish cell death mechanism and to characterize their potential targets. 
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3. Pyrrolo[3,4-h]quinazolines 
 
 
 
 
3.1 Physicochemical properties 
 
BQ compounds are 49 new molecules, therefore physicochemical properties are to be examined. 
Absorbance and emission spectra are determined in DMSO or in phosphate buffer and molar 
extinction coefficient (ε) is calculated, as described in Materials and methods section; the results are 
listed in table 3.1. 
 
Compounds 
λmax abs in 
DMSO (nm) 
ε (M-1*cm-1) in 
DMSO 
λmax abs in 
phosphate buffer 
(nm) 
λmax emiss in 
DMSO (nm) 
BQ1 262 5545 320 376 
BQ2 313 49072 316 417 
BQ3 313 20224 315 374 
BQ4 314 49701 316 398 
BQ5 314 26925 316 405 
BQ6 313 20378 313, 264 365 
BQ7 311 22904 314, 266 371 
BQ8 266, 307 24530 312, 266 374 
BQ9 268 21382 269, 286, 312 370 
BQ10 308 21693 313 376 
BQ11 288 35144 281 424 
BQ12 283 23808 274, 314 420 
BQ13 277 46359 268 422 
BQ14 276 32527 269 422 
BQ15 277 28023 270 421 
BQ16 334 14669 334 373 
Pyrrolo[3,4-h]quinazolines 
________________________________________________________________________________ 
 32 
BQ17 335 14667 335 375 
BQ18 335 15219 335 375 
BQ19 335 14741 335 372 
BQ20 332, 261 13706 329 374 
BQ21 332, 261 15518 331 372 
BQ22 332, 261 17792 330 376 
BQ23 332, 261 9915 328 377 
BQ25 263, 336 23176 262, 336 377 
BQ26 263, 337 28524 262, 338 377 
BQ27 264, 336 15681 266, 341 377 
BQ28 267, 337 14997 266, 338 376 
BQ29 319 24554 334 448 
BQ30 319 27373 332 445 
BQ31 319 28275 332 446 
BQ32 320 19216 334 358 
BQ33 329 32901 342 458 
BQ34 324, 260 33376 327 400 
BQ35 323, 260 25575 335 400 
BQ36 324, 260 29526 332 400 
BQ37 324, 261 27842 331 400 
BQ38 324 26303 332 464 
BQ39 324 29714 327 451 
BQ40 320 32267 332 461 
BQ41 321 33022 332 456 
BQ42 321 31560 327 459 
BQ43 321 33367 327 459 
BQ44 285, 346 78297 278, 344 423 
BQ45 285, 346 108007 304, 361 421 
BQ46 287, 353 69527 298, 366 442 
BQ47 281, 344 79645 290, 361 429 
BQ48 278, 344 94012 267, 356 427 
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BQ49 281, 345 76558 296 433 
BQ50 285, 345 89431 303 428 
 
Tab. 3.1 Spectrophotometric features of pyrrolo[3,4-h]quinazolines. 
 
 
 
3.2 Cytotoxic activity 
 
As pyrrolo[3,4-h]quinazolines are synthesized as antiproliferative compounds, their cytotoxic effect 
is observed in a panel of 5 human tumour cell lines: K-562 (chronic myeloid leukaemia), Jurkat (T-
cell leukaemia), LoVo (colon adenocarcinoma), MCF-7 (breast adenocarcinoma) and A-431 (vulvar 
squamous cell carcinoma ). 
Cytotoxicity is evaluated with MTT test after 72 hours from the incubation with BQ molecules in 
the presence of different concentrations of compounds, as described in Materials and methods 
section; results are summarized in the following table as IC50 (molecules concentration which leads 
to death 50% of cell population). 
 
IC50 (µM) 
Compounds K-562 Jurkat LoVo MCF-7 A-431 
BQ1 > 20 > 20 > 20 > 20 > 20 
BQ2 > 20 > 20 > 20 > 20 > 20 
BQ3 > 20 > 20 > 20 > 20 > 20 
BQ4 > 20 > 20 > 20 > 20 > 20 
BQ5 > 20 > 20 > 20 > 20 > 20 
BQ6 > 20 > 20 > 20 > 20 > 20 
BQ7 > 20 > 20 > 20 > 20 > 20 
BQ8 > 20 > 20 11,3 ± 1,8 > 20 > 20 
BQ9 3,9 ± 0,6 3,7 ± 0,5 5,0 ± 0,4 7,5 ± 0,3 11,3 ± 1,8 
BQ10 3,8 ± 0,4 3,1 ± 0,1 5,4 ± 0,3 14,1 ±0,9 17,3 ± 2,3 
BQ11 > 20 8,4 ± 0,5 6,9 ± 1,9 > 20 > 20 
BQ12 > 20 10,7 ± 1,3 9,1 ± 1,4 > 20 > 20 
BQ13 > 20 > 20 > 20 > 20 > 20 
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BQ14 13,1 ± 2,5 3,2 ± 0,5 9,9 ± 1,8 11,7 ± 0,4 > 20 
BQ15 10,9 ± 2,3 1,3 ± 0,2 7,1 ± 0,7 7,0 ± 0,4 > 20 
BQ16 > 20 > 20 > 20 > 20 > 20 
BQ17 > 20 > 20 > 20 > 20 > 20 
BQ18 19,1 ± 2,1 > 20 6,8 ± 0,4 > 20 > 20 
BQ19 > 20 8,1 ± 1,9 > 20 > 20 > 20 
BQ20 > 20 > 20 10,7 ± 1,1 > 20 > 20 
BQ21 > 20 > 20 > 20 > 20 > 20 
BQ22 > 20 11,7 ± 1,1 12,8 ± 0,2 > 20 11,8± 1,5 
BQ23 > 20 6,3 ±0,4 9,4 ± 0,2 > 20 > 20 
BQ25 > 20 5,0 ± 1,0 > 20 > 20 > 20 
BQ26 > 20 5,9 ± 0,5 10,5 ± 1,2 > 20 > 20 
BQ27 15,3 ± 3,0 3,9 ± 0,8 9,0 ± 1,7 15,3 ± 0,8 > 20 
BQ28 > 20 8,1 ± 1,2 8,0 ± 0,9 > 20 > 20 
BQ29 > 20 > 20 > 20 > 20 > 20 
BQ30 > 20 > 20 > 20 > 20 > 20 
BQ31 > 20 > 20 > 20 > 20 > 20 
BQ32 > 20 > 20 > 20 > 20 > 20 
BQ33 > 20 9,4 ± 0,8 > 20 > 20 > 20 
BQ34 > 20 12,5 ± 1,7 > 20 > 20 > 20 
BQ35 > 20 > 20 > 20 > 20 > 20 
BQ36 > 20 8,5 ± 2,1 > 20 > 20 > 20 
BQ37 > 20 > 20 > 20 > 20 > 20 
BQ38 > 20 > 20 > 20 > 20 > 20 
BQ39 > 20 > 20 > 20 > 20 > 20 
BQ40 > 20 6,2 ± 0,6 14,6 ± 1,6 > 20 > 20 
BQ41 > 20 7,4 ± 0,4 > 20 > 20 > 20 
BQ42 > 20 9,3 ± 1,3 > 20 17,9 ± 1,6 8,5 ± 1,2 
BQ43 > 20 > 20 > 20 > 20 > 20 
BQ44 > 20 8,6 ± 1,9 7,4 ± 1,2 > 20 7,7 ± 0,5 
BQ45 > 20 > 20 > 20 > 20 7,6 ± 1,3 
BQ46 11,0 ± 1,0 > 20 8,8 ± 1,0 > 20 > 20 
BQ47 8,8 ± 1,41 7,3 ± 1,5 9,9 ± 1,0 > 20 9,7 ± 0,4 
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BQ48 > 20 > 20 > 20 > 20 3,0 ± 0,5 
BQ49 > 20 13,0 ± 1,6 9,2 ± 0,6 > 20 > 20 
BQ50 18,6 ± 1,6 > 20 6,9 ± 0,4 > 20 > 20 
 
Tab. 3.2 Antiproliferative activity of BQ molecules (µM). 
 
Some molecules are inactive at the employed concentrations, some others inhibit the proliferation of 
some cell lines (e.g. BQ8, BQ11 and BQ12). The most active compounds are BQ9 and BQ10 (IC50 
values are lower than 15µM in all cell lines) and, next, BQ14 and BQ15, with interesting cytotoxic 
effect. 
Given that many molecules have been analysed, some hypotheses can be developed regarding the 
structure-activity relationships (SAR). 
Pyrrolo[3,4-h]quinazolines are variably substituted at positions 2, 7, 8 and 9. Among quinazoline 
derivatives unsubstituted at position 2, the most cytotoxic ones are substituted at positions 7 and 8 
with lipophilic groups with a remarkable steric hindrance (e.g. ethyl ester – BQ9 and BQ10 – or 
phenyl group – BQ14 and BQ15 – at position 7; p-methyl benzyl group – BQ9 and BQ14 – or p-
methoxybenzyl group – BQ10 and BQ15 – at position 8); if the substitution is observed at only one 
of the two positions, we can see a complete loss of antiproliferative activity (e.g. BQ4, BQ5, BQ6) 
or cytotoxicity is remarkably reduced (e.g. BQ11, BQ12). 
Moreover, cytotoxicity does not increase with the introduction of a substituent at position 2; 
particularly, a carbonyl group reduces cytotoxicity of some molecules or inactivates other 
derivatives. Instead, an amine group can remarkably increase cytotoxicity in Jurkat cells, but it does 
not lead to active compounds for other cell lines. 
In analogy to the quinazoline derivatives which inhibit tyrosine kinase receptor [33, 34, 36, 39-41], 
some molecules with an aniline group at position 2 have been synthesized (BQ44 – BQ50); this 
group does not seem to increase the antiproliferative activity of these compounds, but tested 
compounds are not substituted at positions 7 and 8 as the most active ones in the 2-unsubstituted 
series. 
 
 
3.2.1 Cytotoxicity on resistant tumour cell lines 
 
Although many anticancer drugs in clinical use are effective in the treatment of different kinds of 
tumours, their potential is limited by the development of drug resistance. Resistance can be intrinsic 
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or acquired, but in either case tumours become refractory to a variety of structurally different drugs. 
Thus, the antiproliferative activity is also tested on LoVodoxo cells, a human cancer cell line 
expressing high level of 170-kDa P-glycoprotein (P-gp) drug efflux and resistant to doxorubicine; 
resistance index (RI) is determined comparing IC50 values of the resistant line to the ones obtained 
with LoVo cells. 
 
IC50 (µM) 
Compounds LoVo LoVodoxo RI 
BQ8 11,26 ± 1,76 19,43 ± 0,50 1,72 
BQ9 5,01 ± 0,44 15,17 ± 1,03 3,03 
BQ10 5,44 ± 0,27 8,65 ± 0,13 1,59 
BQ11 6,88 ± 1,89 8,70 ±1,31 1,26 
BQ12 9,11 ± 1,43 12,45 ± 1,33 1,37 
BQ14 9,90 ± 4,83 9,47 ± 2,49 0,96 
BQ15 7,11 ± 0,78 12,50 ± 3,91 1,76 
BQ18 6,80 ± 0,36 9,46 ± 0,28 1,39 
BQ20 10,67 ± 1,08 9,15 ± 0,40 0,86 
BQ22 12,76 ± 0,17 > 20 n.a. 
BQ23 9,36 ± 0,23 > 20 n.a. 
BQ26 10,47 ± 1,16 10,31 ± 1,53 0,98 
BQ27 9,07 ± 1,67 12,92 ± 1,26 1,42 
BQ28 7,96 ± 0,92 12,15 ± 2,11 1,53 
BQ40 14,62 ± 1,64 > 20 n.a. 
BQ44 7,41 ± 1,23 3,50 ± 0,52 0,47 
BQ46 8,77 ± 1,03 > 20 n.a. 
BQ47 9,91 ± 1,03 > 20 n.a. 
BQ49 9,19 ± 0,64 > 20 n.a. 
BQ50 6,92 ± 0,42 > 20 n.a. 
n.a. = not available 
Tab. 3.3 IC50 values on LoVodoxo cell line (µM). 
 
As we can see in this table, many molecules maintain their cytotoxic effect on the resistant 
subclone: IC50 values, in fact, are often similar in both cell lines and RI is next to 1. Nevertheless, 
some compounds are not cytotoxic on the resistant cell line, particularly when they are substituted 
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with an aniline group at position 2, so RI cannot be calculated; instead, other molecules are more 
active on the resistant cell line. 
We can notice two extreme cases: BQ9 has RI of 3,3, probably because it is P glycoprotein 
substrate, but BQ44 cytotoxic activity is higher on LoVodoxo cells (RI = 0,47). 
 
 
3.2.2 Colony formation assay 
 
Colony formation assay is a cell survival test based on the ability of a single cell to grow into a 
colony, hence this test is performed to confirm our previous results about the effectiveness of the 
most active pyrrolo[3,4-h]quinazolines: cell colony formation, in fact, has been found to be a more 
sensitive parameter of toxicity than cell viability since colony formation is assessed while the cells 
are in a state of proliferation, and thus more susceptible to toxic effects. 
In this test, A-431 cells are seeded in their proper medium (7000 cells/well); after 24 hours 
incubation with BQ9, BQ10, BQ14, BQ15 and BQ47 at five different concentrations, the growth 
medium is restored and colony formation is tested every 2-3 days. After 10-15 days, cells are 
stained with crystal violet dye and observed with a light microscope; colony formation percentage is 
then calculated. A colony is formed at least by 50 cells. 
 
 BQ9 BQ10 BQ14 BQ15 BQ47 
50 µM 0% 23,53% 0% 10,39% 4,62% 
20 µM 0% 40,00% 20,22% 20,78% 18,46% 
10 µM 0% 34,12% 34,83% 48,05% 13,85% 
5 µM 3,95% 50,59% 40,45% 46,75% 55,38% 
2,5 µM 32,89% 58,82% 56,18% 64,94% 66,15% 
0 µM (C) 100% 100% 100% 100% 100% 
 
Tab. 3.4 Percentage of colonies formed after incubation with BQ9, BQ10, BQ14, BQ15 and BQ47 at various 
concentrations; C = control. 
 
As we can see, every compound remarkably inhibits colony formation, in almost all cases in a dose-
dependent mode: these results, therefore, confirm our previous data. 
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3.3 Cell death mechanism 
 
Cell death mechanism is investigated with a flow cytometry test performed with the most active 
compounds: BQ9, BQ10, BQ14, BQ15 and BQ47. 
It is very important to distinguish the mechanism that leads to cell death both to understand the 
mechanism of action and to predict some side effects; necrosis, for example, leads to an 
inflammatory reaction, but apoptosis does not: this could be an interesting property to evaluate for a 
potential therapeutic purpose. 
To determine the mechanism that leads to cell death, we perform the Annexin-V/PI test, which uses 
FITC-conjugated Annexin-V to check the translocation of phosphatidylserine (PS) from the inner 
side of the plasma membrane to the outer layer, and propidium iodide (PI) to test the plasmatic 
membrane integrity: the exposure of PS, in fact, is one of the earlier events in apoptosis, but it 
occurs also during cell necrosis; the difference between these two forms of cell death is that during 
the initial stages of apoptosis the cell membrane remains intact, while at the very moment that 
necrosis occurs the cell membrane looses its integrity and becomes leaky [42]. 
This experiment is performed on Jurkat cells. After 24 hours from the incubation with two 
concentrations of each compound, most of the cells is in late apoptosis or in necrotic phase: cells, in 
fact, are positive to both FITC and PI fluorescence. A good percentage of cells treated with BQ47, 
nevertheless, is still in the early apoptotic phase: this can be explained with the lower cytotoxicity 
of this derivative, so cell death could be, in this case, less quick.  
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Fig. 3.1 Early and late apoptotic cells after 24 hours from incubation with BQ9, BQ10 and BQ47 20 µM and 
10 µM; C = control. 
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Fig. 3.2 Early and late apoptotic cells after 24 hours from incubation with BQ14 and BQ15 10 µM and 5 
µM; C = control. 
 
This test is reproduced after 6 hours to verify if apoptosis is the main cell death mechanism for 
these molecules. Reducing incubation period we can see more cells positive to FITC and negative to 
PI in comparison with the control (especially for BQ9, BQ10 and 20 µM BQ47): we can then 
hypothesize that cell death occurs by apoptosis, but this supposition will be further analysed. 
 
 
 
Fig. 3.3 Early and late apoptotic cells after 6 hours from incubation with BQ9, BQ10 and BQ47 20 µM and 
10 µM; C = control. 
 
 
 
3.4 Involvement of mitochondria in cell death mechanism 
 
This feature is analysed to confirm the purposed cell death mechanism: mitochondria, in fact, have 
a key role in apoptosis and their involvement can be detected through some flow cytometric 
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experiments which consider mitochondrial membrane potential and reactive oxygen species (ROS) 
production. 
 
 
3.4.1 Determination of mitochondrial membrane potential 
 
The collapse in mitochondrial membrane potential (∆Ψ) is one of the early events, if not the cause, 
of apoptosis [43]. Intracellular energy produced by the mitochondrial respiratory chain is stored as 
an electrochemical gradient consisting of a transmembrane electrical potential (∆Ψ) of 180 to 200 
mV (negative inside). This energy drives the synthesis of ATP. It is possible to detect variations in 
∆Ψ at the single-cell or single-organelle level using the lipophilic cation JC-1 [44]. 
As described in Materials and methods section, the JC-1 dye undergoes a reversible change in 
fluorescence emission from green to greenish orange as ∆Ψ increases: therefore, cells with high ∆Ψ 
form JC-1 aggregates and fluoresce orange, those with low ∆Ψ contain monomeric JC-1 and 
fluoresce green [45]. 
This assay is performed with Jurkat cells after 6 and 24 hours of incubation with the most active 
molecules and results are summarized in the following graphic. 
Fig. 3.4 Evaluation of mitochondrial membrane potential ∆Ψ after 6 and 24 hours of incubation with BQ9, 
BQ10, BQ14, BQ15 and BQ47; C = control. 
 
In fig. 3.4 we can observe a significant dose-dependent depolarisation of mitochondrial membrane, 
feature that increases with treatment period, so we can hypothesize mitochondria involvement in 
cell death process. 
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3.4.2 Determination of reactive oxygen species (ROS) production 
 
During apoptosis, mitochondria are subject to particular damages that compromise their activity, 
and ROS production is both the cause and the consequence of these injuries. The one-electron 
reduction of molecular oxygen produces a relatively stable intermediate, the superoxide anion (O·2-
), which serves as the precursor of most ROS; the dismutation of superoxide anions by superoxide 
dismutases results in H2O2 production. Subsequent reaction of H2O2 and O·2- can generate the 
highly reactive hydroxyl radical (OH·) [46]. Reactive oxygen species are usually present in cells in 
low concentration, but their production is improved in case of mitochondrial damage and oxidative 
stress, or when defence mechanisms lack. 
To detect ROS production we utilise two probes, hydroethidine (HE) to reveal superoxide anion and 
2’,7’-dichlorodihydrofluorescein-diacetate (DCFDA) to reveal hydrogen peroxide. 
The cytofluorimetric assay is carried out after incubating for 24 hours Jurkat cells with the most 
active compounds at two concentrations. 
Fig. 3.5 Percentage of ROS producing cells after 24 hours incubation; C = control. 
 
As we can see, ROS production is increased compared to control and it is a dose-dependent 
property: consequently, these results confirm the involvement of mitochondria in apoptosis process. 
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3.5 Involvement of lysosomes in cell death mechanism 
 
Even lysosomes can take part in apoptosis process; their implication is detected with Acridine 
Orange (AO), which selectively enters lysosomes and forms aggregates which fluoresce red; if 
lysosomal membrane undergoes rupture, however, this probe migrates to cytosol and, in monomeric 
form, fluoresces green. 
This analysis is led after incubating Jurkat cells for 6 and 24 hours; in the following graph, we can 
appreciate lysosomes involvement in apoptosis, especially after the longer exposure: this could 
suggest their secondary role in apoptosis evolution. 
Fig. 3.6 Evaluation of lysosomal damage after 6 and 24 hours incubation; C = control. 
 
 
 
3.6 Evaluation of EGFR inhibition 
 
As seen before, pyrrolo[3,4-h]quinazolines were synthesized to identify new potential inhibitors of 
tyrosine kinase activity. Particularly, we evaluate their potential activity on EGFR. 
To investigate whether these compounds could block EGF receptor signalling, we employ the 
human skin cancer cell line A-431, which overexpresses the EGFR. 
After treating these cells with compounds for three hours, the blockage in EGFR signalling is 
detected by Western blotting using phospho-specific antibodies against the EGF receptor and the 
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downstream signalling molecules ERK1/2 and AKT. As a positive control, some cell samples are 
treated with a known EGFR inhibitor (AG1478). 
 
 
Fig. 3.7 Cells are serum-starved and either treated for 10 min with 100 ng/ml EGF after 3h of compound 
incubation. Cell lysates (100 µg) are separated by SDS-PAGE and the membrane probed with phospho-
specific antibodies against the EGF receptor (P-Tyr1173) or AKT (Thr308) or ERK1/2 (P-Thr202/P-
Tyr204). In addition, the membranes are probed with antibodies against total EGFR, AKT-1 and ERK 1/2. 1: 
control without EGF; 2: control + EGF; 3: AG1478 5 µM + EGF; 4: BQ9 20 µM + EGF. 
 
 
Fig. 3.8 Cells are serum-starved and either treated for 10 min with 100 ng/ml EGF after 3h of compound 
incubation. Cell lysates (100 µg) are separated by SDS-PAGE and the membrane probed with phospho-
specific antibodies against the EGF receptor (P-Tyr1173) or AKT (Thr308) or ERK1/2 (P-Thr202/P-
Tyr204). In addition, the membranes are probed with antibodies against total EGFR, AKT-1 and ERK 1/2. 1: 
control without EGF; 2: control + EGF; 3: AG1478 5 µM + EGF; 4: BQ10 20 µM + EGF. 
 
 
Fig. 3.9 Cells are serum-starved and either treated for 10 min with 100 ng/ml EGF after 3h of compound 
incubation. Cell lysates (100 µg) are separated by SDS-PAGE and the membrane probed with phospho-
specific antibodies against the EGF receptor (P-Tyr1173) or AKT (Thr308) or ERK1/2 (P-Thr202/P-
Tyr204). In addition, the membranes are probed with antibodies against total EGFR, AKT-1 and ERK 1/2. 1: 
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control without EGF; 2: control + EGF; 3: AG1478 5 µM + EGF; 4: BQ42 20 µM + EGF; 5: BQ45 20 µM 
+ EGF; 6: BQ48 20 µM + EGF. 
 
As we can clearly observe in the upper and left western blot pictures, the analysed compounds are 
not able to inhibit the phosphorylation and the activity of EGFR upon EGF stimulation; moreover, 
the phosphorylation of the downstreaming protein ERK 1/2 and AKT is not also inhibited in the BQ 
treated cells. Consequently, we can hypothesize that EGFR is not the target for BQ compounds. 
 
 
 
3.7 Evaluation of cell cycle 
 
This assay is performed on Jurkat cells after 24 hours incubation to better understand the 
mechanism of action of BQ9, BQ10, BQ14, BQ15 and BQ47; with this flow cytometric test we can 
also draw some conclusions about cell death mechanism. 
DNA contents are different in each phase of the cell cycle so, after fixation in ethanol, cells are 
stained with propidium iodide (PI) dye, which allows to perform rapid determinations of DNA per 
cell; then, we distribute cells according to their DNA contents and we obtain the following graphs. 
 
 
Fig. 3.10 DNA histograms of BQ9, BQ10 and BQ47 20 and 10 µM; C = control. 
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To better analyse cell cycle results, we can calculate cell percentages in each cell cycle phase: 
 
 % G1 % S % G2-M % sub-G1 
Control 59,6 18,0 22,4 8,5 
BQ9 20µM 12,8 8,4 78,8 55,4 
BQ9 10µM 25,5 24,9 49,6 58,3 
BQ10 20µM 18,9 17,1 64,0 62,8 
BQ10 10µM 32,6 20,0 47,4 53,3 
BQ14 10 µM  50,7 17,7 31,6 41,1 
BQ14 5 µM 57,4 16,5 26,1 16,7 
BQ15 10 µM 42,3 13,6 44,1 38,3 
BQ15 5 µM 55,9 15,2 28,9 23,9 
BQ47 20µM 27,4 7,9 64,7 23,3 
BQ47 10µM 36,7 12,2 51,1 17,9 
 
Tab. 3.5 Cell percentages in each cell cycle phase. 
 
In comparison with control, we can notice deep changes in cell cycle profile: for every compound, 
in fact, cells in G2/M phase increase considerably; we can also see a remarkable decrease in G1 
phase cells and the onset of a sub-G1 peak, which is a consequence of the ordered degradation of 
DNA during cell death and represents apoptotic cells. 
 
 
 
3.8 Mitotic index 
 
Since cell cycle studies highlighted a block in G2-M phase, we decided to reveal if the block occurs 
during G2 phase or during mitosis. 
In this assay, nuclei are stained with 4% Giemsa and observed with optical microscope: the amount 
of dispersed chromosomes in the cytoplasm and the disappearance of the nuclear membrane are a 
typical sign of mitotic metaphase. 
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Fig. 3.11 Mitotic index in absence (C) or in presence of 20 µM BQ9, BQ10, BQ14, BQ15 and BQ47. 
 
The most active BQ derivatives induce, at the concentration of 20 µM, a block in mitotic phase in 
treated Jurkat cells. BQ compounds could act as antimitotic drugs so further investigations will be 
performed to confirm their mechanism of action. 
 
 
 
3.9 Evaluation of microtubule network as a possible target 
 
Microtubules with actin and intermediate filaments constitute the cytoskeleton of all eukaryotic 
cells. They are directly involved in many cell functions, such as mitosis, intracellular movement, 
secretion, cell movement, and maintenance of cell shape. Microtubules are dynamic polymers made 
by the assembly of tubulin, a heterodimer consisting of α- and β-tubulin. Microtubule dynamics are 
involved in many microtubule dependent processes in cells, the most important being mitosis. 
During mitosis, the interphase microtubule network completely disassembles and a new assembly 
of microtubules occurs, leading to the mitotic spindle on which the chromosomes attach and 
segregate to the two spindle poles [47]. 
 
 
3.9.1 Microtubule network perturbation 
 
Since the block of cell cycle in mitotic phase is a typical feature of microtubule-targeting drugs, we 
evaluated the perturbation of microtubule network induced by some BQ derivatives. 
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For this test, we observe treated cells by immunofluorescence microscopy. A panel of A-431 cells 
treated for 24 hours with the test compounds is treated with a β-tubulin antibody conjugated with 
the fluorophore FITC. 
 
    
CONTROL BQ9 20 µM BQ10 20 µM BQ14 20 µM 
   
 
BQ15 20 µM BQ47 20 µM Vinblastine 2 µM  
 
Fig. 3.12 Immunofluorescence images of A-431 cells treated with BQ9, BQ10, BQ14, BQ15 and BQ47 20 
µM; control is represented by non-treated cells; as reference compound 2 µM vinblastine is used. 
 
As shown in Fig 3.12, in control cells we can see normal organization and arrangement of tubulin 
network; on the contrary, BQ molecules disrupt microtubule cytoskeleton. Moreover, with the 
exception of BQ47, all compounds induce a clear modification in cell morphology with a “rounded-
up” form, typical feature of cells with occurring microtubule disaggregation. These effects can be 
also observed in vinblastine treated cells (positive control). 
 
 
3.9.2 Effects on microtubule perturbation in vitro 
 
Since the immunofluorescence studies suggest that BQ compounds impair the formation or the 
stability of microtubule network, their effects on tubulin polymerisation in vitro are evaluated. 
Polymerisation is followed by fluorescent enhancement with the incorporation of a fluorescent 
reporter (DAPI) into the microtubules as polymerisation occurs: in fact, the fluorescence of this 
probe raises with microtubules formation. 
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Fig. 3.13 Effect of vinblastine, taxol, BQ9, BQ10, BQ14, BQ15 and BQ47 on microtubule assembly. 
 
In these graphs, at the beginning we can see a slow increase if fluorescence (nucleation phase), then 
an exponential growth and finally a steady state due to the dynamic structure of microtubules. 
While in the control sample the fluorescence increases over time, when reaction is carried out in 
presence of vinblastine or taxol, we observe an inhibition or enhancement of tubulin polymerisation 
respectively. BQ compounds, with the exception of BQ47, reduce tubulin polymerisation in 
concentration-dependent manner: hence, these compounds show an antimitotic action. 
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3.10 Evaluation of antivascular activity in vitro 
 
Since many antimitotic drugs (such as colchicine and combretastatin) can also have an effect on 
tumour immature and neo-formed vessel network, an antivascular effect is assessed performing 
some preliminary tests in vitro: thanks to their action on microtubules, in fact, many antimitotic 
compounds can disrupt cytoskeleton of the rapid-dividing tumour vessel endothelial cells, can affect 
their morphology leading to interferences of cell-to-cell junctional proteins, an increase in vascular 
permeability and a final blood collapse. 
These preliminary assays are carried out on human umbilical vein endothelial cells (HUVECs). 
First of all, we study the effect of these molecules on cellular motility with a scratch test: HUVEC 
monolayers are scratched with a tip and, after different times of incubation with or without BQ, the 
width of the wound is measured. 
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Fig. 3.14 Effect of BQ9, BQ10, BQ14, BQ15 and BQ47 on HUVECs motility; C = control. 
 
All the compounds, at a concentration of 20 µM, inhibit the closure of the scratch in comparison to 
control (after 24 hours, the less active derivative BQ14 induces a closure only of the 40 %, while 
control is completely closed after 20 hours), so they can be considered active. Moreover BQ9 
results very active at 10 µM too, while the other molecules reduce cell motility in a weaker way 
(after 24 hours, they induce a closure of 70-80 % of the scratch). 
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Fig. 3.15 Control and BQ9 20 µM treated HUVECs. 
 
Then, the effect of BQ derivatives on vessel disruption is evaluated in vitro after growing HUVECs 
on Matrigel, which stimulates attachment, migration and differentiation of endothelial cells into 
tubule like structures [48]. After the formation of these capillary-like tubules, HUVECs are 
incubated with compounds at 20 µM concentration for 3 hours. Pictures of capillary network are 
taken after 3 hours of incubation and analysed by AngioJ plug-in of ImageJ software. Particularly, 
we consider 5 parameters that are associated with morphology of capillary network; results are 
presented in Figure 3.16; the pictures of control and of BQ9 treated cells are shown in Figure 3.17 
as representative. 
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Fig. 3.16 Effects of BQ9, BQ10, BQ14, BQ15 and BQ47 on vessel disruption. 
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Fig. 3.17 HUVECs treated with BQ9 20 µM and control. 
 
Quantitative image analysis shows that while BQ9 and BQ15 significantly decrease both 
dimensional (percent of area covered by HUVECs, total length per field and percent of area covered 
by meshes) and topological parameters (number of meshes per field, number of branching points) of 
the capillary-like network, BQ10 and BQ14 are mainly responsible for the decrease of the number 
of meshes and the percentage of their area. BQ47 is not able to induce significant changes in 
HUVECs morphology. 
 
 
 
3.11 Conclusions 
 
In this section 49 new pyrrolo[3,4-h]quinazoline derivatives were analysed. 
These molecules were synthesised at Palermo University by the condensation of a pyrrolo ring to a 
quinazoline structure; this nucleus was then variously substituted at positions 2, 7, 8 and 9. 
After observing BQ compounds chemical and physical properties, we evaluated their cytotoxic 
activity on a wide range of tumour cell lines; some molecules showed an interesting cytotoxicity, 
others were inactive at the employed concentrations. 
Since the number of compounds was reasonable, we can make some structure-activity relationship 
considerations: among quinazoline derivatives unsubstituted at position 2, the most cytotoxic ones 
are substituted at positions 7 and 8 with lipophilic groups with a remarkable steric hindrance. 
Introducing a substitution at position 2, cytotoxicity does not increase; particularly, a carbonyl 
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group reduces cytotoxicity of some molecules or inactivates other derivatives. Instead, an amine 
group can remarkably increase cytotoxicity in Jurkat cells, but it does not lead to active compounds 
for others cell lines. Even an aniline group does not seem to increase the antiproliferative activity of 
these molecules. 
BQ cytotoxic activity was then tested on a resistant tumour cell line, LoVodoxo, and RI was 
calculated; many molecules maintain their cytotoxic effect on the resistant subclone and RI is next 
to 1: this could be really favourable because MDR is one of the most critical problems in 
chemotherapy. 
This study analysed then the most active compounds among this series, BQ9, BQ10, BQ14, BQ15 
and BQ47. These compounds induce cellular death through apoptosis, with a central role of 
mitochondria and lysosomes (involved later compared to mitochondria); this cell death mechanism 
is desirable because, unlike necrosis, it doesn’t lead to an inflammatory response. 
Then the possible mechanism of action was evaluated. 
Because of their structural analogy with some EGFR inhibitors, we tested the most active 
compounds for this mechanism of action; nevertheless, they do not seem to be EGFR inhibitors, but 
further analysis will be carried out. 
Moreover, in cell cycle study we can notice a block in G2-M phase; further analysis demonstrated 
that the block occurs during mitosis. As antimitotic drugs induce a cell cycle block in G2-M phase, 
we decided to verify a possible interference with microtubule network and we observed that BQ 
molecules disrupt microtubule cytoskeleton; moreover, with the exception of BQ47, all compounds 
induce a clear modification in cell morphology with a “rounded-up” form, typical feature of cells 
with occurring microtubule disaggregation. Furthermore, BQ compounds, with the exception of 
BQ47, reduce tubulin polymerisation in concentration-dependent manner: hence, these compounds 
show an antimitotic action. 
Finally, we observed BQ antivascular activity in vitro with positive results: in fact these molecules 
can inhibit cell motility and disrupt a neo-formed HUVEC vessel network. 
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4. Pyrrolo[2,3-h]quinazolines 
 
 
 
 
4.1 Physicochemical properties 
 
Absorbance and emission spectra are determined in DMSO or in phosphate buffer and molar 
extinction coefficient (ε) is calculated; the results are listed in the following table. 
 
Compounds 
λmax abs in 
DMSO (nm) 
ε (M-1*cm-1) in 
DMSO 
λmax abs in 
phosphate buffer 
(nm) 
λmax emiss in 
DMSO (nm) 
LCQ1 347 27300 351 471 
LCQ2 349 34600 351 469 
LCQ3 360 33600 358 439 
LCQ4 362 28700 358 446 
LCQ5 353 22700 350 385 
LCQ6 349 23000 350 392 
LCQ7 352 23800 350 387 
LCQ8 361 27100 356 419 
LCQ9 362 25700 362 417 
LCQ10 363 26400 362 416 
LCQ11 293 45700 284 420 
LCQ12 293 46000 292 426 
LCQ13 290 36500 384 426 
LCQ14 292 32400 272 417 
LCQ15 287 35700 295 418 
LCQ16 336 13200 335 375 
LCQ17 332 26400 333 410 
 
Tab. 4.1 Spectrophotometric features of LCQ molecules. 
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All of these derivatives absorb in the UV range, essential feature for the further studies. 
 
 
 
4.2 Cytotoxic activity 
 
LCQ series is synthesised with the aim of obtaining new photochemotherapeutic agents; their 
cytotoxic effect is observed through MTT test in a panel of 5 human tumour cell lines: K-562 
(chronic myeloid leukaemia), Jurkat (T-cell leukaemia), MCF-7 (breast adenocarcinoma), LoVo 
(colon adenocarcinoma) and A-431 (vulvar squamous cell carcinoma). 
 
IC50 (µM) 
Compounds K-562 Jurkat MCF-7 LoVo A-431 
LCQ1 >20 >20 >20 >20 >20 
LCQ2 >20 >20 >20 >20 >20 
LCQ3 >20 6,0 ± 1,4 >20 >20 >20 
LCQ4 >20 8,4 ± 1,2 >20 >20 >20 
LCQ5 >20 >20 >20 >20 >20 
LCQ6 >20 >20 >20 >20 >20 
LCQ7 >20 >20 >20 >20 >20 
LCQ8 >20 >20 >20 4,2 ± 0,8 >20 
LCQ9 >20 14,0 ± 1,3 >20. 14,2 ± 0,2 >20 
LCQ10 >20 >20 >20. >20 >20 
LCQ11 >20 12,0 ± 1,5 >20 14,7 ± 0,5 9,3 ± 1,2 
LCQ12 >20 4,8 ± 0,8 >20 >20 5,0 ± 0,4 
LCQ13 >20 >20 >20 >20 9,6 ± 0,4 
LCQ14 13,1 ± 1,1 2,9 ± 0,5 >20 >20 1,4 ± 0,1 
LCQ15 >20 >20 >20 >20 >20 
LCQ16 >20 >20 >20 >20 >20 
LCQ17 >20 >20 >20 >20 >20 
 
Tab. 4.2 Antiproliferative activity of LCQ series (µM). 
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Many compounds have no effect on cell proliferation at the employed concentrations, others are 
active only in Jurkat cell line; LCQ14 is the only compound which demonstrates a quite good 
antiproliferative activity, with IC50 values lower than 5 µM against both Jurkat and A-431 cell lines. 
As LCQ series seems to be almost inactive as antiproliferative line, we decided to test its 
photocytotoxicity: in fact, pyrrolo[2,3-h]quinazolines are also heteroanalogues of angelicin and they 
could be photoactivable compounds. 
 
 
 
4.3 Photostability 
 
As pyrrolo[2,3-h]quinazolines absorb in the UV range, we observe their photostability after UVA 
irradiation. 
When irradiated in solution, furocoumarins undergo photolysis [49]. Thus, absorption spectra of 20 
µM derivatives in DMSO are recorded after increasing doses of UVA: these spectra give 
information about the photostability of these molecules and about the formation of other species as 
a consequence of irradiation. 
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Fig. 4.1 Photodegradation of pyrrolo[2,3-h]quinazolines. 
 
As we can see in fig. 4.1, pyrroloquinazolines undergo photolysis after UVA irradiation. In most 
cases, we can find simple reduction of maximum absorbance; moreover, in some spectra we 
observe the presence of isosbestic points that indicate the equilibrium in solution between the two 
species, the non-degraded compound and a photoproduct. 
 
 
 
4.4 Photocytotoxicity 
 
As pyrroloquinazolines absorb in the UV range and demonstrated to undergo photolysis after UVA 
irradiation, we analyse their antiproliferative effect after the irradiation of a panel of 4 human 
tumour cell lines (Jurkat, K-562, LoVo and A-431) in the presence of different concentrations of 
test compounds. Two UVA doses are used: 2,5 and 3,75 J/cm2, corresponding to 10 and 15 
irradiation minutes, respectively. For photocytotoxicity experiments, cells are incubated with 
compounds for 30 minutes prior to irradiation with Wood’s lamps (emitting principally at 365 nm); 
cellular survival is checked by MTT test after 72 hours from irradiation. 
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IC50 (µM) 
Compounds K-562 Jurkat 
 2,5 J/cm2 3,75 J/cm2 2,5 J/cm2 3,75 J/cm2 
LCQ1 >20 >20 >20 >20 
LCQ2 >20 13,69 ± 1,09 >20 >20 
LCQ3 5,70 ± 0,76 4,38 ± 0,44 4,85 ± 0,53 3,47  ± 0,11 
LCQ4 7,96 ± 1,46 2,92 ± 0,42 2,05 ± 0,62 1,08 ± 0,25 
LCQ5 >20 >20 >20 8,42 ± 1,49 
LCQ6 1,44 ± 0,12 0,72 ± 0,28 0,65 ± 0,13 0,39 ± 0,05 
LCQ7 1,71 ± 0,17 0,53 ± 0,09 0,43 ± 0,08 0,28 ± 0,08 
LCQ8 2,38 ± 0,70 1,16 ± 0,20 0,83 ± 0,16 0,46 ± 0,09 
LCQ9 0,74 ± 0,13 0,48 ± 0,08 0,43 ± 0,08 0,21 ± 0,06 
LCQ10 0,75 ± 0,18 0,41 ± 0,05 0,29 ± 0,02 0,23 ± 0,01 
LCQ11 3,51 ± 0,80 1,82 ± 0,39 0,83 ± 0,08 0,55 ± 0,09 
LCQ12 3,90 ± 0,70 2,85 ± 0,20 0,81 ± 0,07 0,52 ± 0,11 
LCQ13 4,06 ± 0,60 2,16 ± 0,28 2,05 ± 0,12 0,68 ± 0,09 
LCQ14 >20 >20 >20 8,53 ± 1,53 
LCQ15 2,63 ± 0,36 1,88 ± 0,35 0,70 ± 0,11 0,50 ± 0,05 
LCQ16 >20 >20 >20 >20 
LCQ17 >20 >20 >20 >20 
 
Tab. 4.3 Photocytotoxicity in some human leukaemia cell lines after UVA irradiation. 
 
IC50 (µM) 
Compounds LoVo A-431 
 2,5 J/cm2 3,75 J/cm2 2,5 J/cm2 3,75 J/cm2 
LCQ1 >20 >20 >20 >20 
LCQ2 >20 >20 >20 >20 
LCQ3 9,72 ± 1,32 6,76 ± 0,57 9,72 ± 1,32 6,76 ± 0,57 
LCQ4 3,07 ± 0,35 2,30 ± 0,24 3,07 ± 0,35 2,30 ± 0,24 
LCQ5 >20 >20 >20 >20 
LCQ6 0,85 ± 0,19 0,54 ± 0,09 0,85 ± 0,19 0,54 ± 0,09 
LCQ7 1,12 ± 0,23 0,59 ± 0,18 1,12 ± 0,23 0,59 ± 0,18 
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LCQ8 1,57 ± 0,12 1,02 ± 0,09 1,57 ± 0,12 1,02 ± 0,09 
LCQ9 0,56 ± 0,07 0,44 ± 0,04 0,56 ± 0,07 0,44 ± 0,04 
LCQ10 0,47 ± 0,07 0,34 ± 0,03 0,47 ± 0,07 0,34 ± 0,03 
LCQ11 0,82 ± 0,14 0,55 ± 0,08 0,82 ± 0,14 0,55 ± 0,08 
LCQ12 2,31 ± 0,17 0,95 ± 0,09 2,31 ± 0,17 0,95 ± 0,09 
LCQ13 2,80 ± 0,29 1,43 ± 0,15 2,80 ± 0,29 1,43 ± 0,15 
LCQ14 15,21 ± 1,97 9,61 ± 1,32 15,21 ± 1,97 9,61 ± 1,32 
LCQ15 0,88 ± 0,11 0,48 ± 0,11 0,88 ± 0,11 0,48 ± 0,11 
LCQ16 >20 >20 >20 >20 
LCQ17 >20 >20 >20 >20 
 
Tab. 4.4 Photocytotoxicity in some human solid tumour cell lines after UVA irradiation. 
 
Almost all compounds reveal dose-dependent IC50 values after UVA irradiation; the most active 
compounds are LCQ9 and LCQ10, with sub-micromolar IC50 results. 
Given the considerable number of compounds tested, we can formulate some hypotheses regarding 
the structure-activity relationships. 
Pyrrolo[3,2-h]quinazolines are variably substituted at positions 2, 8 and 9. The substitution at 
position 2 seems to play a key role in the induction of phototoxicity: in fact, the antiproliferative 
effect is maximum with an amino group and decreases progressively with an aniline group, a 
carbonyl group and without substituent. At position 9, the increase in steric hindrance (p-
methoxybenzyl ≈ benzyl > methyl) improves the phototoxicity, as the introduction of an 
ethoxycarbonyl moiety at position 8, which even leads to active compounds. 
 
 
4.4.1 Photocytotoxicity in the presence of scavengers 
 
In this assay, we test the antiproliferative activity of LCQ9 and LCQ10, the most photocytotoxic 
compounds of this series, in the presence of some scavengers, which should exert their defensive 
action over treated LoVo cells. 
In this test, we use three different scavengers: DMTU (1,3-dimethyl-2-thiourea), which protects 
cells by the formation of hydroxyl radical, DABCO (1,4-diazabicyclo[2.2.2]octane), which prevents 
the formation of singlet oxygen, and BHA (butylhydroxyanisole), which prevents the formation of 
alkyl radicals. 
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We carry out this test with one UVA dose (2,5 J/cm2, corresponding to 10 minutes) and one 
compound concentration (0,5 µM); photocytotoxicity is evaluated after 72 hours with MTT test. 
Results are expressed as IC50. 
 
 LCQ9 LCQ10 
No scavengers 64,53 ± 6,19 49,83 ± 5,20 
+ DMTU 85,90 ± 3,72 57,58 ± 3,26 
+ DABCO 64,32 ± 3,09 43,52 ± 1,19 
+ BHA 66,75 ± 6,46 48,71 ± 2,05 
 
Tab. 4.5 IC50 values in presence of scavengers. 
 
These results highlight the protective effect of DMTU on the treated cells; instead, the other 
scavengers do not seem to prevent radical formation: therefore, we can hypothesise that LCQ9 and 
LCQ10 act through the formation of hydroxyl radical. 
 
 
 
4.5 Evaluation of cell cycle 
 
Cell cycle studies are performed in the dark with the most cytotoxic compound LCQ14. In this 
study there is no evidence of cell death because no changes are detected for cells treated; 
particularly, there is not the onset of the characteristic apoptotic peak (sub-G1). These results 
suggest the hypothesis that pyrrolo[2,3-h]quinazolines are cytostatic compounds. 
 
 
 
4.6 Cell death mechanism 
 
Cell death mechanism is investigated with the most active compounds by a flow cytometry test. 
At first, we performed this test with LCQ14, the most cytotoxic derivative on Jurkat cell line, and 
results were adequate to the previous ones: in fact, there is no evidence of cell death because there 
is no increase in the percentage of cells showing exposure of phosphatidylserine nor in the number 
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of cells with augmented permeability to propidium iodide. The hypothesis that pyrrolo[2,3-
h]quinazolines are cytostatic but not cytotoxic molecules in the dark is confirmed. 
Then, we carried out this test with the two most phototoxic compounds, LCQ9 and LCQ10, at the 
concentration of 1 or 2 µM, 24 and 3 hours after irradiation (2,5 J/cm2). 
Fig. 4.2 Early and late apoptotic cells 24 hours after irradiation (2,5 J/cm2); cells are incubated with LCQ9 
and LCQ10 2 and 1 µM; IC = irradiated control. 
 
After 24 hours, most cells are in late apoptotic phase, so we monitor cell death after a shorter 
incubation time. 
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Fig. 4.3 Early and late apoptotic cells 3 hours after irradiation (2,5 J/cm2); cells are incubated with LCQ9 
and LCQ10 2 and 1 µM; IC = irradiated control. 
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After 3 hours from irradiation, an increase in early apoptotic cells is detected in a dose-dependent 
manner relative to control; a small percentage of necrotic cells is also detected, but the primary 
mechanism of cell death seems to be apoptosis. 
 
 
 
4.7 Involvement of mitochondria in cell death mechanism 
 
Psoralens and UVA are known to induce cell death by apoptosis with the involvement of 
mitochondria. Thus, we decided to perform some assays to evaluate a possible role of mitochondria 
in LCQ photoinduced apoptosis. 
 
 
4.7.1 Determination of mitochondrial membrane potential 
 
This test is performed with JC-1 dye after 3 hours irradiation; the mitochondrial membrane potential 
is monitored by the fluorescence of this probe. Results are summarised in the following graphic. 
 
Fig. 4.4 Cells percentage with loss of mitochondrial membrane potential 3 hours after irradiation (2,5 
J/cm2) of cells treated with LCQ9 and LCQ10 2 and 1 µM; IC = irradiated control. 
 
Irradiated Jurkat cells (2,5 J/cm2), in the presence of LCQ9 and LCQ10 2 and 1 µM, undergo a 
depolarisation of mitochondrial membrane, with a dose-dependent shift in fluorescence respect to 
control, so we can hypothesise mitochondrial involvement in cell death process. 
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4.7.2 Determination of ROS production 
 
ROS production is examined by flow cytometry 6 hours after irradiation of Jurkat cells in the 
presence of LCQ9 and LCQ10 2 and 1 µM. 
 
Fig. 4.5 Percentage of ROS production 6 hours after irradiation (2,5 J/cm2) and treatment with LCQ9 and 
LCQ10 2 and 1 µM; IC = irradiated control. 
 
As we can see, ROS production is increased compared to control and it is a dose-dependent 
property: consequently, these results confirm the involvement of mitochondria in apoptosis process. 
 
 
 
4.8 Involvement of lysosomes in cell death mechanism 
 
To investigate the integrity of lysosomes after UVA irradiation (2,5 J/cm2) in the presence of LCQ9 
and LCQ10, this flow cytometric analysis is performed with acridine orange dye; the percentage of 
Jurkat cells with intact lysosomes is evaluated by assaying red fluorescence after AO staining. 
As we can see in the following graph, a significant extent of lysosomal damage is photo-induced by 
LCQ9 and LCQ10 3 hours after irradiation, so we can hypothesise lysosomal involvement in cell 
death mechanism. 
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Fig.4.6 Cells percentage with lysosomal damage 3 hours after irradiation (2,5 J/cm2) in the presence of 
LCQ9 and LCQ10 2 and 1 µM; IC = irradiated control. 
 
 
 
4.9 Photoreaction with the main biomolecules: lipid 
peroxidation 
 
This test is performed to reveal any possible photodamage against lipids 24 hours after the 
irradiation of Jurkat cells in the presence of LCQ9 and LCQ10. This assay involves the reaction of 
one molecule of malondialdehyde (MDA), which is a secondary product of lipid peroxidation, with 
two molecules of thiobarbituric acid (TBA): the formation of the reaction product, a pink complex, 
is monitored by fluorescence. This test is performed on the supernatant medium. 
Fig. 4.7 Lipid peroxidation induced by LCQ9 and LCQ10 2 and 1 µM 24 hours after irradiation (2,5 J/cm2); 
IC = irradiated control. 
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In this graphic, a significant dose-dependent production of thiobarbituric acid reactive substances 
(TBARs) is observed. 
 
 
 
4.10 Conclusions 
 
LCQ series is composed by 17 pyrrolo[2,3-h]quinazolines synthesised at Palermo University by the 
condensation of a pyrrolo ring to a quinazoline structure; this nucleus was then variously substituted 
at positions 2, 8 and 9. 
Some of these derivatives inhibit cell proliferation in vitro, even in the absence of UVA irradiation, 
but their antiproliferative effect is very limited; furthermore, after flow cytometric analysis, 
cytotoxic activity can be excluded, because there is no increase in cell death in treated samples 
relative to control cells, but cytostatic activity could explain the decrease in cellular metabolic 
activity observed by MTT tests. 
Pyrrolo[3,2-h]quinazolines absorb in the UV and UVA range; many of these derivatives undergo 
photolysis, as evidenced by monitoring changes in their structure after UVA irradiation. Most 
derivatives show remarkable photocytotoxicity in many human tumour cell lines, reaching IC50 
values in the low micromolar and sub-micromolar range. The most phototoxic compounds, LCQ9 
and LCQ10, bear an amino group, an ethoxycarbonyl moiety and a substituent of steric bulk at 
positions 2, 8 and 9, respectively. 
Pyrrolo[3,2-h]quinazolines induce significant cell death by apoptosis at only 3 hours after UVA 
irradiation, as detected by Annexin V/PI test. We also carried out some experiments to determine 
that two organelles, mitochondria and lysosomes, are heavily involved in inducing cell death: in 
fact, we demonstrated the collapse in mitochondrial membrane potential, the production of ROS 
and the disruption of lysosomal integrity induced by the most active compounds. 
Finally, the lipid peroxidation induced by pyrrolo[3,2-h]quinazolines could explain their phototoxic 
activity. 
Although we have identified a very interesting class of new derivatives with high phototoxicity, 
further studies are required to identify the initial signals and downstream events involved in the 
activation of apoptosis and to reveal the mechanism of action. 
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5. Pyrazolo[3,4-h]quinolines 
 
 
 
 
5.1 Physicochemical properties 
 
As pyrazoloquinolines are new compounds, their physicochemical properties are determined. 
Absorbance and emission spectra are determined in DMSO or in phosphate buffer and molar 
extinction coefficient (ε) is calculated. 
 
Compounds 
λmax abs in 
DMSO (nm) 
ε (M-1*cm-1) in 
DMSO 
λmax abs in 
phosphate buffer 
(nm) 
λmax emiss in 
DMSO (nm) 
PZQ1 402, 267 15856 383, 262 429 
PZQ2 401, 268 33255 384 429 
PZQ3 402, 272 29730 381 432 
PZQ4 401, 268 30532 382 428 
PZQ5 401, 265 21690 383 431 
PZQ6 402, 265 24988 380 429 
PZQ7 403, 263 32686 412 437 
PZQ8 403, 263 34073 414 435 
PZQ9 403, 263 32057 384 439 
PZQ10 404, 262 29176 383 438 
PZQ11 403, 263 31815 384 437 
PZQ12 402, 262 30079 384 533 
PZQ13 404, 264 31358 383 444 
PZQ14 405, 264 32825 388 449 
PZQ15 405, 262 29620 384 445 
PZQ16 342, 268 35660 338, 262 382 
PZQ17 342, 262 35657 364 385 
PZQ18 342, 262 37471 343 386 
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PZQ19 338, 262 36739 349 380 
PZQ20 338, 262 23660 355 379 
PZQ21 338, 263 23655 357 384 
PZQ22 342, 262 40331 364 397 
PZQ23 393, 262 38908 373, 262 434 
PZQ24 396, 262 20530 358 417 
PZQ25 396, 262 36168 380 434 
PZQ26 396, 262 41061 379 437 
PZQ27 336, 262 46288 341 395 
PZQ28 337, 262 49615 337, 273 390 
PZQ29 369, 280 30094 397 443 
PZQ30 373, 280 65204 414, 301 463 
PZQ31 371, 281 47623 379, 279 426 
PZQ32 379, 279 44061 379, 279 442 
PZQ33 347, 264 40785 358, 268 422 
PZQ34 344, 262 42862 354, 262 434 
PZQ35 403 2865 378 427 
PZQ36 406 39003 410 436 
PZQ37 338 106096 359 425 
PZQ38 344 32075 361 420 
Ang 306 14602 305 413 
 
Tab. 5.1 Spectrophotometric properties of PZQ series. 
 
PZQ compounds absorb in UV range; these molecules exhibit a batochromic shift compared to 
angelicin (λmax = 305 nm), selected as reference compound: this could be explained with the 
conjugation with substituents in position 3 and 7. 
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5.2 Photostability 
 
As pyrrolo[2,3-h]quinazolines absorb in the UV range, we observe their photostability after UVA 
irradiation. The absorption spectra of 20 µM derivatives in DMSO are recorded after increasing 
doses of UVA: these spectra give information about the photostability of these molecules and about 
the formation of other species as a consequence of irradiation. 
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PZQ7
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PZQ15
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Fig. 5.1 Photodegradation of pyrazolo[3,4-h]quinolines. 
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Most of these molecules does not undergo photolysis; for those which degrade, furthermore, we 
detect a weak reduction of the maximum peak and the presence of one or more isosbestic points that 
reveal the presence of photoproduct(s) in equilibrium with the non-degraded molecule. 
  
 
 
5.3 Antiproliferative activity 
 
PZQ series is synthesised to obtain new photochemotherapeutic agents; their cytotoxic effect is 
observed through MTT test in a panel of 7 human tumour cell lines, K-562 (chronic myeloid 
leukaemia), Jurkat (T-cell leukaemia), HL-60 (promyelocytic leukaemia), A-431 (vulvar squamous 
cell carcinoma), A-549 (alveolar basal epithelial adenocarcinoma), LoVo (colon adenocarcinoma) 
and MCF-7 (breast adenocarcinoma), and in an immortalised line of human keratinocytes, NCTC-
2544. 
First of all, we observe the results obtained in the dark. 
 
IC50 (µM) 
Compounds K-562 Jurkat HL-60 
PZQ1 >20 >20 >20 
PZQ2 >20 >20 >20 
PZQ3 >20 >20 >20 
PZQ4 >20 >20 >20 
PZQ5 >20 >20 >20 
PZQ6 >20 4,55 ± 0,66 >20 
PZQ7 >20 >20 >20 
PZQ8 >20 >20 >20 
PZQ9 >20 >20 >20 
PZQ10 >20 >20 >20 
PZQ11 >20 >20 >20 
PZQ12 13,85 ± 1,81 >20 >20 
PZQ13 >20 11,26 ± 1,08 >20 
PZQ14 >20 >20 >20 
PZQ15 >20 >20 >20 
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PZQ16 >20 >20 >20 
PZQ17 >20 12,07 ± 1,69 >20 
PZQ18 >20 8,43 ± 1,43 6,10 ± 1,35 
PZQ19 >20 9,80 ± 1,60 7,17 ± 0,77 
PZQ20 >20 13,24 ± 1,67 >20 
PZQ21 >20 11,35 ± 1,22 >20 
PZQ22 >20 12,54 ± 1,53 >20 
PZQ23 >20 > 20 >20 
PZQ24 >20 >20 >20 
PZQ25 >20 >20 >20 
PZQ26 >20 >20 >20 
PZQ27 >20 >20 >20 
PZQ28 >20 >20 >20 
PZQ29 >20 >20 >20 
PZQ30 >20 >20 >20 
PZQ31 >20 >20 >20 
PZQ32 >20 >20 >20 
PZQ33 >20 >20 >20 
PZQ34 >20 >20 >20 
PZQ35 >20 13,59 ± 1,70 11,56 ± 1,98 
PZQ36 >20 >20 >20 
PZQ37 >20 >20 >20 
PZQ38 >20 >20 >20 
 
Tab.5.2 Antiproliferative activity of PZQ series in some human leukaemia cell lines in the dark. 
 
 
IC50 (µM) 
Compounds A-431 A-549 LoVo MCF-7 NCTC-2544 
PZQ1 >20 >20 >20 >20 > 20 
PZQ2 >20 >20 >20 >20 >20 
PZQ3 4,41 ± 0,42 10,81 ± 0,66 >20 11,53 ± 2,02 >20 
PZQ4 >20 >20 >20 >20 >20 
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PZQ5 >20 >20 >20 >20 >20 
PZQ6 2,68 ± 0,32 6,41 ± 0,48 >20 >20 > 20 
PZQ7 2,87 ± 0,58 6,25 ± 0,68 >20 11,17 ± 1,29 > 20 
PZQ8 1,63 ± 0,33 4,04 ± 0,42 >20 8,54 ± 1,20 > 20 
PZQ9 >20 >20 >20 >20 > 20 
PZQ10 >20 >20 >20 >20 > 20 
PZQ11 >20 >20 >20 >20 > 20 
PZQ12 >20 >20 >20 >20 > 20 
PZQ13 >20 >20 >20 >20 > 20 
PZQ14 >20 >20 >20 >20 > 20 
PZQ15 >20 >20 >20 >20 > 20 
PZQ16 >20 >20 >20 >20 > 20 
PZQ17 >20 >20 >20 >20 > 20 
PZQ18 >20 >20 >20 >20 > 20 
PZQ19 >20 >20 >20 >20 >20 
PZQ20 >20 >20 >20 >20 > 20 
PZQ21 >20 >20 >20 >20 > 20 
PZQ22 >20 >20 >20 >20 > 20 
PZQ23 0,83 ± 0,11 5 ± 0,93 >20 6,38 ± 0,90 8,39 ± 1,27 
PZQ24 >20 >20 >20 > 20 > 20 
PZQ25 >20 >20 >20 >20 > 20 
PZQ26 >20 >20 >20 >20 >20 
PZQ27 >20 >20 >20 >20 > 20 
PZQ28 >20 >20 >20 >20 > 20 
PZQ29 >20 12,49 ± 0,65 >20 9,26 ± 1,41 3,96 ± 0,92 
PZQ30 2,64 ± 0,17 9,03 ± 0,65 >20 8,36 ± 0,75 5,61 ± 1,17 
PZQ31 7,66 ± 0,69 >20 >20 > 20 9,78 ± 1,10 
PZQ32 8,94 ± 0,92 >20 >20 9,60 ± 1,48 6,50 ± 0,73 
PZQ33 2,95 ± 0,45 0,32 ± 0,75 >20 7,51 ± 1,30 4,72 ± 0,70 
PZQ34 8,73 ± 0,25 >20 >20 16,19 ± 1,34 14,03 ± 1,27 
PZQ35 >20 >20 >20 > 20 > 20 
PZQ36 >20 >20 >20 >20 >20 
PZQ37 >20 >20 >20 >20 >20 
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PZQ38 >20 >20 >20 >20 >20 
 
Tab. 5.3 Cytotoxicity in some human solid tumour cell lines in the dark. 
 
Pyrazolo[3,4-h]quinazolines do not seem to be particularly cytotoxic molecules at the employed 
concentrations, especially in the leukaemic cell lines; the human solid tumour cell lines demonstrate 
to be more sensitive to these compounds, particularly when the derivative has a carbonyl group at 
position 2. 
Then, we analyse the photocytotoxicity in the presence of different concentrations of test 
compounds; two UVA doses are used: 1,25 and 2,5 J/cm2 in leukaemic cell lines, corresponding to 
5 and 10 irradiation minutes, or 2,5 and 3,75 J/cm2 in carcinoma cell lines, corresponding to 10 and 
15 irradiation minutes, respectively. For photocytotoxicity experiments, cells are incubated with the 
molecules for 30 minutes prior to irradiation with Wood’s lamps (emitting principally at 365 nm); 
cellular survival is checked by MTT test after 72 hours from irradiation. 
 
IC50 (µM) 
Compounds Jurkat HL-60 
 1,25 J/cm2 2,5 J/cm2 1,25 J/cm2 2,5 J/cm2 
PZQ1 >20 >20 >20 >20 
PZQ2 >20 >20 >20 >20 
PZQ3 >20 >20 >20 >20 
PZQ4 >20 6,88 ± 0,94 < 20 5,06 ± 0,63 
PZQ5 11,27 ± 1,46 3,95 ± 0,34 11,48 ± 1,69 2,76 ± 0,40 
PZQ6 >20 >20 >20 >20 
PZQ7 >20 >20 >20 >20 
PZQ8 >20 >20 >20 >20 
PZQ9 >20 >20 >20 >20 
PZQ10 >20 6,99 ± 1,15 >20 >20 
PZQ11 >20 5,67 ± 0,93 >20 6,79 ± 0,54 
PZQ12 >20 5,21 ± 0,84 >20 4,82 ± 0,24 
PZQ13 >20 2,81 ± 0,41 >20 2,44 ± 0,24 
PZQ14 >20 3,01 ± 0,60 >20 2,88 ± 0,42 
PZQ15 >20 6,68 ± 0,42 >20 7,65 ± 0,55 
PZQ16 >20 12,68 ± 1,58 >20 9,79 ± 1,46 
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PZQ17 3,65 ± 0,47 0,71 ± 0,13  2,83 ± 0,31 0,79 ± 0,06 
PZQ18 2,48 ± 0,48 1,40 ± 0,15  3,83 ± 0,57 1,30 ± 0,16 
PZQ19 1,93 ± 0,14 0,90 ± 0,13  3,78 ± 0,53 0,81 ± 0,15 
PZQ20 1,95 ± 0,35 1,34 ± 0,27  3,42 ± 0,46 0,53 ± 0,14 
PZQ21 0,72 ± 0,11 0,43 ± 0,13 4,03 ± 1,19 0,48 ± 0,10 
PZQ22 1,15 ± 0,18 0,64 ± 0,15 5,29 ± 1,21 0,72 ± 0,12 
PZQ23 >20 >20 > 20 >20 
PZQ24 >20 >20 > 20 >20 
PZQ25 >20 >20 > 20 7,67 ± 1,10 
PZQ26 >20 >20 > 20 >20 
PZQ27 4,47 ± 0,72 1,81 ± 0,35 5,38 ± 1,01 1,71 ±0,27 
PZQ28 9,93 ± 1,31 6,43 ± 0,55 7,71 ± 1,41 4,69 ± 0,67 
PZQ29 > 20 >20 > 20 > 20 
PZQ30 > 20 > 20 > 20 > 20 
PZQ31 0,20 ± 0,06 0,10 ± 0,02 0,39 ± 0,05 0,31 ± 0,02 
PZQ32 0,58 ± 0,15 0,25 ± 0,04 0,61 ± 0,08 0,44 ± 0,03 
PZQ33 4,23 ± 1,15 0,96 ± 0,20 1,80 ± 0,31 1,2 ± 0,14 
PZQ34 1,50 ± 0,40 0,54 ± 0,11 0,82 ± 0,09 0,6 ± 0,09 
PZQ35 > 20 4,97 ± 1,45 > 20 7,17 ± 1,44 
PZQ36 > 20 >20 > 20 > 20 
PZQ37 > 20 >20 > 20 > 20 
PZQ38 > 20 > 20 > 20 9,09 ± 1,38 
 
Tab. 5.4 Photocytotoxicity in some human leukaemia cell lines after UVA irradiation. 
 
 
IC50 (µM) 
Compounds MCF-7 LoVo A-549 
 2,5 J/cm2 3,75 J/cm2 2,5 J/cm2 3,75 J/cm2 2,5 J/cm2 3,75 J/cm2 
PZQ1 >20 >20 >20 >20 >20 >20 
PZQ2 >20 >20 >20 >20 >20 >20 
PZQ3 >20 >20 >20 >20 >20 14,06 ± 0,94 
PZQ4 >20 >20 >20 14,52 ± 2,43 >20 >20 
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PZQ5 12,99 ± 1,48 10,43 ± 0,60 >20 10,14 ± 1,09 13,33 ± 2,20 8,97 ± 0,95 
PZQ6 >20 >20 >20 >20 14,14 ± 1,51 9,53 ± 1,18 
PZQ7 >20 >20 >20 >20 >20 > 20 
PZQ8 >20 >20 >20 >20 >20 >20 
PZQ9 >20 >20 >20 >20 >20 >20 
PZQ10 >20 >20 >20 >20 >20 >20 
PZQ11 >20 >20 >20 13,04 ± 2,2 >20 >20 
PZQ12 >20 12,62 ± 1,04 >20 13,06 ± 1,85 >20 13,02 ± 1,27 
PZQ13 12,67 ± 1,74 9,01 ± 1,19 13,12 ± 1,05 7,54 ± 1,17 >20 8,40 ± 1,43 
PZQ14 >20 >20 >20 11,11 ± 2,40 >20 >20 
PZQ15 >20 >20 >20 >20 >20 >20 
PZQ16 >20 >20 >20 >20 >20 >20 
PZQ17 2,47 ± 0,34 1,84 ± 0,19 3,14 ± 0,30 1,10 ± 0,20 7,56 ± 0,69 2,89 ± 0,32 
PZQ18 4,00 ± 0,51 3,05 ± 0,48 5,32 ± 0,51 1,41 ± 0,25 10,37 ± 1,48 5,74 ± 1,04 
PZQ19 3,13 ± 0,35 1,59 ± 0,12 5,73 ± 0,78 1,78 ± 0,36 14,32 ± 2,66 4,80 ± 0,50 
PZQ20 5,15 ± 1,10 2,52 ± 0,40 9,84 ± 1,14 2,99 ± 0,87 13,33 ± 3,48 6,61 ± 0,85 
PZQ21 7,09 ± 2,02 1,69± 0,18 5,53 ± 1,00 0,73 ± 0,15 5,28 ± 1,03 1,49 ± 0,35 
PZQ22 2,53 ± 0,24 1,18 ± 0,12 3,56 ± 0,63 0,53 ± 0,11 4,02 ± 0,44 1,52 ± 0,15 
PZQ23 7,32 ± 0,98 9,85 ± 0,93 >20 >20 >20 >20 
PZQ24 >20 >20 >20 >20 >20 >20 
PZQ25 >20 >20 >20 >20 >20 >20 
PZQ26 >20 >20 >20 >20 >20 >20 
PZQ27 >20 >20 2,79 ± 0,47 1,13 ± 0,41 3,68 ± 0,61 2,30 ± 0,31 
PZQ28 >20 >20 5,81 ± 0,32 4,30 ± 0,52 6,99 ± 0,74 4,67 ± 0,56 
PZQ29 >20 >20 >20 >20 >20 >20 
PZQ30 >20 >20 >20 >20 5,39 ± 0,93 4,26 ± 0,67 
PZQ31 0,33 ±0,06 0,17 ± 0,03 0,16 ± 0,03 0,04 ± 0,02 0,26 ± 0,25 0,08 ± 0,03 
PZQ32 0,29 ± 0,03 0,14 ± 0,03 0,19 ± 0,03 0,09 ± 0,02 0,27 ± 0,01 0,08 ± 0,03 
PZQ33 5,36 ± 0,73 3,23 ± 0,46 1,43 ± 0,30 0,71 ± 0,15 3,09 ± 1,15 0,75 ± 0,21 
PZQ34 1,23 ± 0,14 0,59 ±0,07 0,42 ± 0,02 0,16 ± 0,03 0,35 ± 0,05 0,09 ± 0,03 
PZQ35 > 20 9,89 ± 1,45 11,08 ± 1,24 3,72 ± 0,91 >20 6,64 ± 1,12 
PZQ36 >20 >20 >20 4,12 ± 1,19 >20 >20 
PZQ37 >20 >20 >20 >20 >20 >20 
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PZQ38 >20 >20 >20 2,67 ± 0,84 >20 5,74 ± 0,96 
 
Tab. 5.5 Photocytotoxicity in some human solid tumour cell lines after UVA irradiation 
 
After UVA irradiation, many molecules show an interesting antiproliferative activity; the 
photocytotoxicity is, in most cases, dose-dependent. 
The most active compounds in this series are PZQ31 and PZQ32, with sub-micromolar IC50 values 
in all the tested cell lines, but also PZQ21 and PZQ22 show a remarkable effect, with sub-
micromolar IC50 results in some cell lines. 
Given that many derivatives have been analysed, some hypotheses can be developed regarding the 
SAR. 
These molecules are variously substituted at positions 1, 2, 3 and 7; some of them have a double 
bond at positions 5-6, so they become fully aromatic compounds. 
Among the derivatives devoid of the double bond 5,6, the ones with a methoxyl group at position 2 
(e.g. PZQ21 and PZQ22) are more effective than molecules with a carbonyl group. In addition, a 
hydrophobic substitution at position 7 (i.e. benzyl, phenyl, chlorophenyl, methoxyphenyl) increases 
photocytotoxicity, as the presence of a phenyl sulfonyl group at position 3 respect to an 
ethoxycarbonyl derivative. 
The most active fully aromatic analogues maintain the methoxyl substitution at position 2 (a 
carbonyl group leads to a loss of activity) and the hydrophobic group at position 7; finally, the 
insertion of a methyl group at position 1 produces the most active compounds of this line, PZQ31 
and PZQ32. 
 
 
5.3.1 Photocytotoxicity in the presence of scavengers 
 
In this assay, we test the antiproliferative activity of the most photocytotoxic compounds of this 
series in the presence of some scavengers. 
In this test, we use six different scavengers: E vitamin (α-tocopherol) and reduced glutathione 
(GSH), which protect cells by the formation of alkyl radicals, sodium azide (NaN3) and DABCO 
(1,4-diazabicyclo[2.2.2]octane), which prevent the formation of singlet oxygen, and DMTU (1,3-
dimethyl-2-thiourea) and mannitol, which protect cells by the formation of hydroxyl radical. 
We carry out this test with one UVA dose (2,5 J/cm2, corresponding to 10 minutes) and with a 
compound concentration next to its IC50 (0,5 µM for PZQ21, 0,75 µM for PZQ22 and 0,20 µM for 
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PZQ31 and PZQ32); photocytotoxicity is evaluated after 72 hours with MTT test on treated Jurkat 
cells. 
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Fig. 5.2 Scavenger effect on treated cells after UVA irradiation (2,5 J/cm2). 
 
As we can see in figure 5.2, α-tocopherol is successful in protecting cells from PZQ injuries; since 
E vitamin is a lipophilic protein which can protect membranes, we can hypothesise the involvement 
of the plasma membrane structure in the mechanism of action of these compounds. 
The other scavengers exert their action in a different manner for each molecule: for example, for 
PZQ21 and PZQ22, the lipophilic scavengers increase the cellular viability, while all scavengers 
lead to an augmentation of cellular survival in the presence of PZQ31. Anyway, the most effective 
scavengers have often lipophilic features, so they probably have the same localization of 
pyrazoloquinolines. 
 
 
5.3.2 Colony formation assay 
 
In this test, A-549 cells are seeded in their proper medium (7000 cells/well); after 30 minutes 
incubation with PZQ21, PZQ22, PZQ31 and PZQ32 at four different concentrations and UVA 
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irradiation (2,5 J/cm2), cells are stored in their growth medium. After 5 days, cells are stained with 
crystal violet dye and observed with a light microscope; colony formation percentage is then 
calculated. A colony is formed at least by 50 cells. 
 
 
 
 
 
 C IC  
 
 
 
 
PZQ21 4 µM PZQ21 2 µM PZQ21 1 µM PZQ21 0,5 µM 
 
 
 
 
PZQ22 4 µM PZQ22 2 µM PZQ22 1 µM PZQ22 0,5 µM 
 
 
 
 
PZQ31 0,5 µM PZQ31 0,25 µM PZQ31 0,125 µM PZQ31 0,0625 µM 
 
 
 
 
PZQ32 0,5 µM PZQ32 0,25 µM PZQ32 0,125 µM PZQ32 0,0625 µM 
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Fig.5.3 Colony formation assay; C = control, IC = irradiated control. 
 
All these molecules can inhibit the colony formation at the employed concentrations in a dose-
dependent manner; particularly, PZQ31 and PZQ32 can inhibit the colony formation at sub-
micromolar concentrations, whereas PZQ21 and PZQ22 are effective at the concentration of about 1 
µM. 
 
 
 
5.4 Cell death mechanism 
 
Cell death mechanism is studied with the most active compounds at the concentration of 1 or 2 µM, 
24 and 3 hours after irradiation (2,5 J/cm2), by the Annexin V/PI flow cytometry test. 
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Fig. 5.4 Early and late apoptotic cells 24 hours after irradiation (2,5 J/cm2); cells are incubated with 
PZQ21, PZQ22, PZQ31 and PZQ32 2 and 1 µM; IC = irradiated control. 
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After 24 hours, most cells are in late apoptotic phase, so we monitor cell death after a shorter 
incubation time. 
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Fig. 5.4 Early and late apoptotic cells 3 hours after irradiation (2,5 J/cm2); cells are incubated with PZQ21, 
PZQ22, PZQ31 and PZQ32 2 and 1 µM; IC = irradiated control. 
 
After 3 hours from irradiation, an increase in early apoptotic cells is detected in a dose-dependent 
manner relative to control; a small percentage of necrotic cells is also detected, but the primary 
mechanism of cell death seems to be apoptosis. 
 
 
 
5.5 Involvement of mitochondria in cell death mechanism 
 
Psoralens and UVA are known to induce cell death by apoptosis with the involvement of 
mitochondria. Thus, we decided to perform some assays to evaluate a possible role of mitochondria 
in PZQ photoinduced apoptosis. 
 
 
5.5.1 Determination of mitochondrial membrane potential 
 
This test is performed with JC-1 dye after 24 and 3 hours from irradiation; the mitochondrial 
membrane potential is monitored by the fluorescence of this probe. 
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Fig. 5.5 Cells percentage with loss of mitochondrial membrane potential 24 hours after irradiation (2,5 
J/cm2) of cells treated with PZQ21, PZQ22, PZQ31 and PZQ32 2 and 1 µM; IC = irradiated control. 
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Fig. 5.6 Cells percentage with loss of mitochondrial membrane potential 3 hours after irradiation (2,5 
J/cm2) of cells treated with PZQ21, PZQ22, PZQ31 and PZQ32 2 and 1 µM; IC = irradiated control. 
 
In these graphics, we can detect a depolarisation of mitochondrial membrane, with a dose-
dependent shift in fluorescence respect to control. Particularly, PZQ31 is the most effective 
compound; 3 hours after irradiation, we can see about 40% cells with collapsed membrane potential 
and, 24 hours after irradiation, about 80% cells. Moreover, for this compound we do not notice 
concentration-dependence but only UV dose-dependence because of the high efficacy of this 
molecule.  
Consequently, we can hypothesise mitochondrial involvement in cell death process. 
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5.5.2 Determination of ROS production 
 
ROS production is examined by flow cytometry 24 hours after irradiation of Jurkat cells in the 
presence of PZQ21, PZQ22, PZQ31 and PZQ32 at the concentration of 2 µM. 
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Fig. 5.7 Percentage of ROS production 24 hours after irradiation (2,5 J/cm2) and treatment with PZQ21, 
PZQ22, PZQ31 and PZQ32 2  µM; IC = irradiated control. 
 
PZQ21 and PZQ22 induce a weak increase in ROS production at the employed concentration; 
instead PZQ31 and PZQ32 provoke a remarkable increment in this parameter. These results confirm 
the previous ones, that is the mitochondria involvement in cell death process, in a weaker manner 
for PZQ21 and PZQ22 and preferentially for PZQ32 and, above all, for PZQ31. 
 
 
 
5.6 Involvement of lysosomes in cell death mechanism 
 
To investigate the involvement of lysosomes in the apoptotic mechanism 24 and 3 hours after UVA 
irradiation (2,5 J/cm2), we perform a flow cytometric analysis with acridine orange dye; the 
percentage of Jurkat cells with intact lysosomes is evaluated by assaying red fluorescence after AO 
staining. 
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Fig.5.8 Cells percentage with lysosomal damage 24 hours after irradiation (2,5 J/cm2) in the presence of 
PZQ21, PZQ22, PZQ31 and PZQ32 2 and 1 µM; IC = irradiated control. 
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Fig.5.9 Cells percentage with lysosomal damage 3 hours after irradiation (2,5 J/cm2) in the presence of 
PZQ21, PZQ22, PZQ31 and PZQ32 2 and 1 µM; IC = irradiated control. 
 
The lysosomal damage is concentration- and time-dependent; as seen before, PZQ32 and 
particularly PZQ31 are the most active compounds. In conclusion, we can hypothesise lysosomal 
involvement in cell death mechanism. 
 
 
 
5.7 Photoreaction with the main biomolecules 
 
In this section we analyse PZQ photoreaction with lipids and proteins. 
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5.7.1 Lipid peroxidation 
 
This assay is performed to reveal a potential photodamage against lipids 24 hours after the 
irradiation of Jurkat cells in the presence of test compounds at the concentration of 2 µM. 
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Fig. 5.10 Lipid peroxidation induced by PZQ21, PZQ22, PZQ31 and PZQ32 2 µM 24 hours after 
irradiation (2,5 J/cm2); IC = irradiated control. 
 
In these graphics, a considerable production of thiobarbituric acid reactive substances (TBARs) is 
observed, particularly in cells extract (intracellular MDA) respect to the surnatant (extracellular 
MDA): therefore, lipids could be a possible target of pyrazoloquinolines. 
 
 
5.7.2 Photoreaction with model proteins 
 
This experiment is carried out to discover another potential target of these molecules; particularly, 
tryptophan (Trp) and tyrosine (Tyr) amino acids are monitored through fluorimetric assays to detect 
a photodamage on two model proteins, BSA (bovine serum albumin, containing Trp) and RNAse 
(containing Tyr, but not Trp). 
Protein solutions treated with 10 µM test compounds are irradiated with different UVA doses (1,25 
J/cm2, 2,5 J/cm2, 5 J/cm2, 7,5 J/cm2, 11,25 J/cm2, 15 J/cm2) and fluorescence spectra are recorded: 
changes in protein fluorescence highlight a photodamage. 
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Fig. 5.11 Photoreaction with BSA and RNAse of test compounds in the presence of increasing UVA doses. 
 
In these graphs we can notice that PZQ compounds cause a dose-dependent decrease in Trp 
fluorescence and this fact is indicative of photoreaction with BSA; instead, RNAse fluorescence is 
not affected by irradiation in the presence of these compounds. 
 
 
 
5.8 Conclusions 
 
In this section 38 new pyrazolo[3,4-h]quinolines were analysed. 
These molecules were synthesised at Palermo University as angelicin heteroanalogues: the aim was 
to obtain new photochemotherapic agents with minor toxicity but improved activity in comparison 
to angelicin and its derivatives. Their nucleus was variously substituted at positions 1, 2, 3 and 7 
and some of them have a double bond at positions 5-6, so they become fully aromatic compounds. 
Some of these derivatives inhibit cell proliferation in vitro, even in the absence of UVA irradiation, 
but their antiproliferative effect is not very pronounced at the employed concentrations, especially 
in the leukaemic cell lines; the human solid tumour cell lines demonstrated to be more sensitive to 
these compounds, particularly when the derivative has a carbonyl group at position 2. 
Pyrazolo[3,4-h]quinolines absorb in the UV and UVA range, but in most cases they do not undergo 
photolysis, as we can see by monitoring changes in their structure after UVA irradiation; for those 
which degrade, we detected a weak reduction of the maximum peak and the presence of one or 
more isosbestic points that reveal the presence of photoproduct(s) in equilibrium with the non-
degraded molecule. 
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Most derivatives showed remarkable photocytotoxicity in many human tumour cell lines, reaching 
IC50 values in the sub-micromolar range; the most phototoxic compounds are PZQ21, PZQ22, 
PZQ31 and PZQ32. Among the not fully aromatic derivatives, the ones with a methoxyl group at 
position 2 (e.g. PZQ21 and PZQ22) are more effective than molecules with a carbonyl group. In 
addition, a hydrophobic substitution at position 7 increases photocytotoxicity, as the presence of a 
phenyl sulfonyl group at position 3 respect to an ethoxycarbonyl derivative. The most active fully 
aromatic analogues maintain the methoxyl substitution at position 2 (a carbonyl group leads to a 
loss of activity) and the hydrophobic group at position 7; finally, the insertion of a methyl group at 
position 1 produces the most active compounds of this line, PZQ31 and PZQ32. 
With flow cytometry studies we demonstrated that these compounds induce cellular death through 
apoptosis, with the involvement of mitochondria and lysosomes (involved later respect to 
mitochondria); PZQ31 is the most effective compound. 
Finally, we analysed the photoreaction with the main biomolecules to identify a possible target of 
these derivatives: these compounds react with lipids and BSA, so lipids and proteins could be 
involved in their mechanism of action. This is confirmed by the protective action of α-tocopherol on 
cells treated with test compounds; since E vitamin is a lipophilic protein that can protect 
membranes, we can hypothesise the involvement of the membrane structures in the mechanism of 
action of these compounds. 
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6. Materials and methods 
 
 
 
 
6.1 Materials 
 
• Compounds: 104 new compounds, synthesised at Palermo University by Cirrincione’s 
group, were analysed: 
- BQ1: 6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline 
- BQ2: 8-methyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline 
- BQ3: 8-benzyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline 
- BQ4: 8-(4-methylbenzyl)-6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline 
- BQ5: 8-(4-methoxybenzyl)-6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline 
- BQ6: ethyl 9-methyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline-7-carboxylate 
- BQ7: ethyl 8,9-dimethyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline-7-carboxylate 
- BQ8: ethyl 8-benzyl-9-methyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline-7-
carboxylate 
- BQ9: ethyl 9-methyl-8-(4-methylbenzyl)-6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline-
7-carboxylate 
- BQ10: ethyl 9-methyl-8-(4-methoxybenzyl)-6,8-dihydro-5H-pyrrolo[3,4-
h]quinazoline-7-carboxylate 
- BQ11: 7-phenyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline 
- BQ12: 8-methyl-7-phenyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline 
- BQ13: 8-benzyl-7-phenyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline 
- BQ14: 8-(4-methylbenzyl)- 7-phenyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline 
- BQ15: 8-(4-methoxybenzyl)- 7-phenyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline 
- BQ16: 8-methyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazolin-2-amine 
- BQ17: 8-benzyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazolin-2-amine 
- BQ18: 8-(4-methylbenzyl)-6,8-dihydro-5H-pyrrolo[3,4-h]quinazolin-2-amine 
- BQ19: 8-(4-methoxybenzyl)-6,8-dihydro-5H-pyrrolo[3,4-h]quinazolin-2-amine 
- BQ20: ethyl 2-amino-6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline-7-carboxylate 
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- BQ21: ethyl 2-amino-8,9-dimethyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline-7-
carboxylate 
- BQ22: ethyl 2-amino-8-benzyl-9-methyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline-
7-carboxylate 
- BQ23: ethyl 2-amino-9-methyl-8-(4-methylbenzyl)-6,8-dihydro-5H-pyrrolo[3,4-
h]quinazoline-7-carboxylate 
- BQ25: 8-methyl-7-phenyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazolin-2-amine 
- BQ26: 8-benzyl-7-phenyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazolin-2-amine 
- BQ27: 8-(4-methylbenzyl)-7-phenyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazolin-2-
amine 
- BQ28: 8-(4-methoxybenzyl)-7-phenyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazolin-2-
amine 
- BQ29: 8-methyl-3,5,6,8-tetrahydro-2H-pyrrolo[3,4-h]quinazolin-2-one 
- BQ30: 8-benzyl-3,5,6,8-tetrahydro-2H-pyrrolo[3,4-h]quinazolin-2-one 
- BQ31: 8-(4-methylbenzyl)-3,5,6,8-tetrahydro-2H-pyrrolo[3,4-h]quinazolin-2-one 
- BQ32: 8-(4-methoxybenzyl)-3,5,6,8-tetrahydro-2H-pyrrolo[3,4-h]quinazolin-2-one 
- BQ33: 8-phenyl-3,5,6,8-tetrahydro-2H-pyrrolo[3,4-h]quinazolin-2-one 
- BQ34: ethyl 8,9-dimethyl-2-oxo-3,5,6,8-tetrahydro-2H-pyrrolo[3,4-h]quinazoline-7-
carboxylate 
- BQ35: ethyl 8-benzyl-9-methyl-2-oxo-3,5,6,8-tetrahydro-2H-pyrrolo[3,4-
h]quinazoline-7-carboxylate 
- BQ36: ethyl 8-(4-methylbenzyl)-9-methyl-2-oxo-3,5,6,8-tetrahydro-2H-pyrrolo[3,4-
h]quinazoline-7-carboxylate 
- BQ37: ethyl 8-(4-methoxybenzyl)-9-methyl-2-oxo-3,5,6,8-tetrahydro-2H-
pyrrolo[3,4-h]quinazoline-7-carboxylate 
- BQ38: 8,9-dimethyl-3,5,6,8-tetrahydro-2H-pyrrolo[3,4-h]quinazolin-2-one 
- BQ39: 8-benzyl-9-methyl-3,5,6,8-tetrahydro-2H-pyrrolo[3,4-h]quinazolin-2-one 
- BQ40: 8-methyl-7-phenyl-3,5,6,8-tetrahydro-2H-pyrrolo[3,4-h]quinazolin-2-one 
- BQ41: 8-benzyl-7-phenyl-3,5,6,8-tetrahydro-2H-pyrrolo[3,4-h]quinazolin-2-one 
- BQ42: 8-(4-methylbenzyl)-7-phenyl-3,5,6,8-tetrahydro-2H-pyrrolo[3,4-
h]quinazolin-2-one 
- BQ43: 8-(4-methoxybenzyl)-7-phenyl-3,5,6,8-tetrahydro-2H-pyrrolo[3,4-
h]quinazolin-2-one 
- BQ44: 8-methyl-N-phenyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazolin-2-amine 
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- BQ45: 8-benzyl-N-phenyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazolin-2-amine 
- BQ46: N,8-diphenyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazolin-2-amine 
- BQ47: ethyl 2-anilino-8,9-dimethyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline-7-
carboxylate 
- BQ48: ethyl 2-anilino-9-methyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline-7-
carboxylate 
- BQ49: ethyl 2-anilino-8-benzyl-9-methyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline-
7-carboxylate 
- BQ50: 2-anilino-8-benzyl-7-phenyl-6,8-dihydro-5H-pyrrolo[3,4-h]quinazoline 
- LCQ1: 9-methyl-3,5,6,9-tetrahydro-2H-pyrrolo[3,2-h]quinazolin-2-one 
- LCQ2: 9-benzyl-3,5,6,9-tetrahydro-2H-pyrrolo[3,2-h]quinazolin-2-one 
- LCQ3: ethyl 9-methyl-3,5,6,9-tetrahydro-2H-pyrrolo[3,2-h]quinazolin-2-one-8-
carboxylate 
- LCQ4: ethyl 9-benzyl-3,5,6,9-tetrahydro-2H-pyrrolo[3,2-h]quinazolin-2-one-8-
carboxylate 
- LCQ5: 2-amine-9-methyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline 
- LCQ6: 2-amine-9-benzyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline 
- LCQ7: 2-amine-9-(4-methoxybenzyl)-6,9-dihydro-5H-pyrrolo[3,2-h] quinazoline 
- LCQ8: ethyl 2-amino-9-methyl-6,9-dihydro-5H-pyrrolo[3,2-h] quinazoline-8-
carboxylate 
- LCQ9: ethyl 2-amino-9-benzyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-8-
carboxylate 
- LCQ10: ethyl 2-amino-9-(4-methoxybenzyl)-6,9-dihydro-5H-pyrrolo[3,2-h] 
quinazoline-8-carboxylate 
- LCQ11: 2-anilino-9-methyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline 
- LCQ12: 2-anilino-9-benzyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline 
- LCQ13: 2-anilino-9-(4-methoxybenzyl)-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline 
- LCQ14: ethyl 2-anilino-9-methyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline-8-
carboxylate 
- LCQ15: ethyl 2-anilino-9-(4-methoxybenzyl)-6,9-dihydro-5H-pyrrolo[3,2-
h]quinazoline-8-carboxylate 
- LCQ16: 9-benzyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline 
- LCQ17: 9-phenyl-6,9-dihydro-5H-pyrrolo[3,2-h]quinazoline 
- PZQ1: 3-(phenylsulfonyl)-1,5,6,7-tetrahydro-2H-pyrazolo[3,4-h]quinolin-2-one 
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- PZQ2: 7-methyl-3-(phenylsulfonyl)-1,5,6,7-tetrahydro-2H-pyrazolo[3,4-h]quinolin-
2-one 
- PZQ3: 7-phenyl-3-(phenylsulfonyl)-1,5,6,7-tetrahydro-2H-pyrazolo[3,4-h]quinolin-
2-one 
- PZQ4: 7-benzyl-3-(phenylsulfonyl)-1,5,6,7-tetrahydro-2H-pyrazolo[3,4-h]quinolin-
2-one 
- PZQ5: 7-(2-chlorophenyl)-3-(phenylsulfonyl)-1,5,6,7-tetrahydro-2H-pyrazolo[3,4-
h]quinolin-2-one 
- PZQ6: 7-(3-chlorophenyl)-3-(phenylsulfonyl)-1,5,6,7-tetrahydro-2H-pyrazolo[3,4-
h]quinolin-2-one 
- PZQ7: 7-(4-chlorophenyl)-3-(phenylsulfonyl)-1,5,6,7-tetrahydro-2H-pyrazolo[3,4-
h]quinolin-2-one 
- PZQ8: 7-(4-mthoxyphenyl)-3-(phenylsulfonyl)-1,5,6,7-tetrahydro-2H-pyrazolo[3,4-
h]quinolin-2-one 
- PZQ9: 1,7-dimethyl-3-(phenylsulfonyl)-1,5,6,7-tetrahydro-2H-pyrazolo[3,4-
h]quinolin-2-one 
- PZQ10: 1-methyl-7-phenyl-3-(phenylsulfonyl)-1,5,6,7-tetrahydro-2H-pyrazolo[3,4-
h]quinolin-2-one 
- PZQ11: 7-benzyl-1-methyl-3-(phenylsulfonyl)-1,5,6,7-tetrahydro-2H-pyrazolo[3,4-
h]quinolin-2-one 
- PZQ12: 7-(2-chlorophenyl)-1-methyl-3-(phenylsulfonyl)-1,5,6,7-tetrahydro-2H-
pyrazolo[3,4-h]quinolin-2-one 
- PZQ13: 7-(3-chlorophenyl)-1-methyl-3-(phenylsulfonyl)-1,5,6,7-tetrahydro-2H-
pyrazolo[3,4-h]quinolin-2-one 
- PZQ14: 7-(4-chlorophenyl)-1-methyl-3-(phenylsulfonyl)-1,5,6,7-tetrahydro-2H-
pyrazolo[3,4-h]quinolin-2-one 
- PZQ15: 7-(4-methoxyphenyl)-1-methyl-3-(phenylsulfonyl)-1,5,6,7-tetrahydro-2H-
pyrazolo[3,4-h]quinolin-2-one 
- PZQ16: 2-methoxy-7-methyl-3-(phenylsulfonyl)-6,7-dihydro-5H-pyrazolo[3,4-
h]quinoline 
- PZQ17: 2-methoxy-7-phenyl-3-(phenylsulfonyl)-6,7-dihydro-5H-pyrazolo[3,4-
h]quinoline 
- PZQ18: 2-methoxy-7-benzyl-3-(phenylsulfonyl)-6,7-dihydro-5H-pyrazolo[3,4-
h]quinoline 
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- PZQ19: 7-(2-chlorophenyl)-2-methoxy-3-(phenylsulfonyl)-6,7-dihydro-5H-
pyrazolo[3,4-h]quinoline 
- PZQ20: 7-(3-chlorophenyl)-2-methoxy-3-(phenylsulfonyl)-6,7-dihydro-5H-
pyrazolo[3,4-h]quinoline 
- PZQ21: 7-(4-chlorophenyl)-2-methoxy-3-(phenylsulfonyl)-6,7-dihydro-5H-
pyrazolo[3,4-h]quinoline 
- PZQ22: 2-methoxy-7-(4-methoxyphenyl)-3-(phenylsulfonyl)-6,7-dihydro-5H-
pyrazolo[3,4-h]quinoline 
- PZQ23: 7-(4-chlorophenyl)-3-(ethoxycarbonyl)-1,5,6,7-tetrahydro-2H-pyrazolo[3,4-
h]quinolin-2-one 
- PZQ24: 7-(4-methoxyphenyl)-3-(ethoxycarbonyl)-1,5,6,7-tetrahydro-2H-
pyrazolo[3,4-h]quinolin-2-one 
- PZQ25: 7-(4-chlorophenyl)-1-methyl-3-(ethoxycarbonyl)-1,5,6,7-tetrahydro-2H-
pyrazolo[3,4-h]quinolin-2-one 
- PZQ26: 7-(4-methoxyphenyl)-1-methyl-3-(ethoxycarbonyl)-1,5,6,7-tetrahydro-2H-
pyrazolo[3,4-h]quinolin-2-one 
- PZQ27: 7-(4-chlorophenyl)-2-methoxy-3-(ethoxycarbonyl)-6,7-dihydro-5H-
pyrazolo[3,4-h]quinoline 
- PZQ28: 2-methoxy-7-(4-methoxyphenyl)-3-(ethoxycarbonyl)-6,7-dihydro-5H-
pyrazolo[3,4-h]quinoline 
- PZQ29: 7-(4-chlorophenyl)-3-(phenylsulfonyl)-1,7-dihydro-2H-pyrazolo[3,4-
h]quinolin-2-one 
- PZQ30: 3-(phenylsulfonyl)-7-(4-methoxyphenyl)-1,7-dihydro-2H-pyrazolo[3,4-
h]quinolin-2-one 
- PZQ31: 7-(4-chlorophenyl)-3-(phenylsulfonyl)-1-methyl-1,7-dihydro-2H-
pyrazolo[3,4-h]quinolin-2-one 
- PZQ32: 3-(phenylsulfonyl)-1-methyl-7-(4-methoxyphenyl)-1,7-dihydro-2H-
pyrazolo[3,4-h]quinolin-2-one 
- PZQ33: 7-(4-chlorophenyl)-3-(phenylsulfonyl)-2-methoxy-7H-pyrazolo[3,4-
h]quinoline 
- PZQ34: 3-(phenylsulfonyl)-2-methoxy-7-(4-methoxyphenyl)-7H-pyrazolo[3,4-
h]quinoline 
- PZQ35: 1-benzyl-7-(4-chlorophenyl)-3-(phenylsulfonyl)-1,5,6,7-tetrahydro-2H-
pyrazolo[3,4-h]quinolin-2-one 
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- PZQ36: 1-benzyl-3-(phenylsulfonyl)-7-(4-methoxyphenyl)-1,5,6,7-tetrahydro-2H-
pyrazolo[3,4-h]quinolin-2-one 
- PZQ37: 2-benzyloxy-7-(4-chlorophenyl)-3-(phenylsulfonyl)-6,7-dihydro-5H-
pyrazolo[3,4-h]quinoline 
- PZQ38: 2-benzyloxy-3-(phenylsulfonyl)-7-(4-methoxyphenyl)-6,7-dihydro-5H-
pyrazolo[3,4-h]quinoline 
• DMSO (dimethyl sulfoxide), Sigma Aldrich (IT) 
• Phosphate buffer, Sigma Aldrich (IT) 
• RPMI-1640 Medium, Sigma Aldrich (IT) 
• HAM’S (Nutrient Mixture F-12 HAM), Sigma Aldrich (IT) 
• DMEM (Dulbecco’s Modified Eagle’s Medium), Sigma Aldrich (IT) 
• Foetal bovine serum (FBS), Invitrogen  (IT) 
• Penicillin-Streptomycin solution, Sigma Aldrich (IT) 
• HBSS (Hank’s Balanced Saline Solution), Sigma Aldrich (IT) 
• Trypsin, Sigma Aldrich (IT) 
• MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide), Sigma Aldrich (IT) 
• PBS (Phosphate Buffer Solution) 10 mM, p.H. = 7.2 
• Isopropanol, Carlo Erba (IT) 
• HCl, Carlo Erba (IT) 
• Tripan Blue, Sigma Aldrich (IT) 
• Crystal violet (4-[(4-dimethylaminophenyl)-phenyl-methyl]-N,N-dimethyl-aniline), Sigma 
Aldrich (IT) 
• Annexin V/PI staining kit, Roche (DE) 
• JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazol-carbocyanine), Molecular 
Probes Eugene (OR, USA) 
• AO (Acridine Orange), Sigma Aldrich (IT) 
• HE (hydroethidine), Molecular Probes Eugene (OR, USA) 
• DCHF-DA (2’,7’-dichlorofluorescin diacetate), Molecular Probes Eugene (OR, USA) 
• 70% ethanol, Carlo Erba (IT) 
• Cell cycle staining kit, Sigma Aldrich (IT) 
• EGF (100 ng/ml), Sigma Aldrich (IT) 
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• Lysis buffer (50 mM Tris-HCl pH 8.5, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 1 
mM DTT, 30 mM NaPPi, 10 mM NaF, 1 mM Na3VO4, 100 nM okadaic acid, complete 
protease inhibitors), Roche (DE) 
• PVDF membrane, Bio Rad (IT) 
• Casein, Sigma Aldrich (IT) 
• Tween-20, Sigma Aldrich (IT) 
• Polyclonal anti-Phospho-EGFR (Tyr1173), Santa Cruz (TX, USA) 
• Anti-Phospho-ERK1/2 (P-p42/p44) (Thr202/Tyr204), Cell Signaling (USA) 
• Anti-EGFR, Santa Cruz (TX, USA) 
• Alkaline phosphatase, Jackson Immunoresearch Laboratories (PA, USA) 
• Giemsa stain, Sigma Aldrich (IT) 
• Microtubule polymerisation assay kit Cytoskeleton (Denver, USA) 
• DAPI (4',6-diamidino-2-phenylindole), Sigma Aldrich (IT) 
• M200 Medium, Invitrogen (IT) 
• LSGS (Low Serum Growth Supplement), Invitrogen 
• Matrigel, BD Biosciences (NJ, USA) 
• BHT (butylhydroxytoluen), Sigma Aldrich (IT) 
• SDS (sodium dodecyl sulfate), Sigma Aldrich (IT) 
• TCA (trichloroacetic acid), Sigma Aldrich (IT) 
• TBA (thiobarbituric acid), Sigma Aldrich (IT) 
• BHA (butylhydroxyanisole), Sigma Aldrich (IT) 
• DABCO (1,4 diazabicyclo [2,2,2] octane), Acros Organics (N.J., USA) 
• DMTU (N-N’ dimethyl thiourea), Sigma Aldrich (IT) 
• α-tocopherol, Sigma Aldrich (IT) 
• GSH (reduced glutathione), Sigma Aldrich (IT) 
• NaN3 (sodium azide), Sigma Aldrich (IT) 
• MAN (mannitol), Sigma Aldrich (IT) 
• BSA (Bovine Serum Albumin), Sigma Aldrich (IT) 
• RNAse A (A ribonuclease), Sigma Aldrich (IT) 
• UV-Vis double beam instrument Lambda 12, Perkin-Elmer (MA, USA) 
• LS50B fluorimeter, Perkin-Elmer (MA, USA) 
• Microtiter plate reader, Bio Rad (IT) 
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• HPW 125 lamps, Philips (NL) and Cole-Parmer Instrument Company radiometer (IL, USA), 
equipped with a 365-CX sensor 
• Flow cytometer BD FACSCalibur, Beckton Dickinson (NY, USA) 
• Fluorescence microplate reader Fluoroskan Ascent FL, Labsystems (IT) 
• Optical microscope Optika ProVision XDS, Optika (IT) 
• Fluorescence microscope Nikon Eclipse 80i 
• Confocal microscope TCS SP5, Leica (DE) 
• HERACell incubator, Kendro (CT, USA) 
• Centrifuge, Beckman Coulter (IT) 
• Water bath, Julabo (DE) 
• Vortex, IKA Works (NC, USA) 
• Sonorex TK52, Bandelin (DE) 
• Polaris cabinet, Steril 
• Technical balance, KERN (DE) 
• Analytical balance, Sartorius (DE) 
• Digital photocamera Kodak DC256 
 
 
 
6.2 Methods 
 
6.2.1 Spectrophotometric determinations 
 
All spectrophotometric measures were performed using UV-Vis Perkin Elmer instrument 
(Lambda12, double beam). For all the compounds, absorption spectra, molar extinction coefficients 
(ε) and determination of maxima peaks were carried out both in DMSO and phosphate buffer (10 
mM and pH=7,2), solvents compatible with cells, at the concentration of 10 and 20 µM, 
respectively. 
Solubility of all molecules in aqueous medium was determined through the construction of a 
calibration curve by spectrophotometer method in the range of concentration used for experiments 
and at maximum absorption peak. 
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6.2.2 Spectrofluorimetric determinations 
 
Fluorimetric spectra were recorded in phosphate buffer or in DMSO by a Perkin Elmer LS50B 
fluorimeter with 10 µM solutions. 
 
 
6.2.3 Irradiation procedures 
 
HPW 125 Philips lamps, mainly emitting at 365 nm, were used for irradiation experiments. The 
spectral irradiance of the source was 4,0 mW/cm2 as measured, at the sample level, by a Cole-
Parmer Instrument Company radiometer (IL, USA), equipped with a 365-CX sensor. 
 
 
6.2.4 Photostability 
 
In this test, 20 µM compounds solutions in DMSO were irradiated with known UVA doses: 0 
minutes, 5 minutes, 15 minutes, 30 minutes with 0,25 J/(cm2 x min). The absorption spectra were 
recorded with UV-Vis double beam instrument Lambda 12, Perkin-Elmer. 
 
 
6.2.5 Cell cultures 
 
For experiments of cellular viability, various human cell lines were used: Jurkat, K-562, HL-60, 
LoVo, LoVodoxo, MCF-7, A-431, A-549, NCTC-2544. 
Jurkat were human lymphoblastoid cells taken in 14 years old boy in 1976; they were grown in 
RPMI medium supplemented with 115 units/ml of penicillin G, 115 µg/ml streptomycin and 10% 
heat-inactivated foetal bovine serum (complete RPMI 1640 medium). Cells were kept at 37 °C in 
5% CO2 humidified atmosphere and re-seeded into fresh medium three times a week. 
K-562 were obtained by a 53 year old woman with chronic myelogenous leukaemia in terminal 
blast crisis; cells were kept at 37 °C in 5% CO2 humidified atmosphere and re-seeded into fresh 
medium (complete RPMI 1640) three times a week. 
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HL-60 were promyelocytic leukaemia cells taken in a woman of 35 years in 1976; they were grown 
in complete RPMI 1640 medium, kept at 37 °C in 5% CO2 humidified atmosphere and re-seeded 
into fresh medium three times a week 
LoVo were human intestinal adenocarcinoma cells taken in a 56 years old man in 1971. LoVo were 
grown in HAM’S F12 medium, supplemented with 115 units/ml of penicillin G, 115 µg/ml 
streptomycin and 10% heat-inactivated foetal bovine serum (complete HAM’S medium); cells were 
kept at 37 °C in 5% CO2 humidified atmosphere, trypsinised and re-seeded into fresh medium twice 
a week. 
LoVodoxo were doxorubicin resistant subclone of LoVo cells [50]; they were grown in complete 
HAM’S F12 medium supplemented with doxorubicin (0,1 µg/ml). 
MCF-7 were human breast adenocarcinoma cells. They were grown in DMEM medium 
supplemented with 115 units/ml of penicillin G, 115 µg/ml streptomycin and 10% heatinactivated 
foetal bovine serum (complete DMEM medium); cells were kept at 37 °C in 5% CO2 humidified 
atmosphere, trypsinised and reseeded into fresh medium once a week. 
A-431 were obtained by a vulvar squamous cell carcinoma; they were grown in complete DMEM 
medium, kept at 37 °C in 5% CO2 humidified atmosphere, trypsinised and reseeded into fresh 
medium twice a week. 
A-549 derived from a non-small cell lung cancer. They were grown in complete DMEM medium; 
cells were kept at 37 °C in 5% CO2 humidified atmosphere, trypsinised and reseeded into fresh 
medium twice a week. 
NCTC-2544 were human immortalized keratinocytes; they were grown in complete DMEM 
medium, kept at 37 °C in 5% CO2 humidified atmosphere, trypsinised and re-seeded into fresh 
medium twice a week. 
 
 
6.2.6 Cellular toxicity and phototoxicity 
 
Individual wells of a 96-well tissue culture microtiter plate were inoculated with 100 ml of 
complete medium containing 5x103 cells; plates were harvested at 37 °C in a humidified 5% CO2 
incubator for 24 hours prior to the cell viability experiments. Drugs were dissolved in DMSO and 
then were diluted with Hank’s Balanced Salt Solution (HBSS pH=7,2) for phototoxicity 
experiments or in the appropriated complete medium for the cytotoxicity ones. 
In cytotoxicity tests, after medium removal, 100 µl of the drug solution at serial concentrations were 
added to each well and incubated at 37 °C for 72 hours. 
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In phototoxicity experiments, after medium removal, 100 µl of the drug solution at serial 
concentrations were put into each well and incubated at 37 °C for 30 minutes and then irradiated 
(1,25, 2,5 or 3,75 J/cm2); after irradiation, drug solution was replaced by cellular medium and plates 
were incubated for 72 hours at 37 °C. 
After the period of incubation, in both cases cell viability was assayed by the MTT [(3-(4,5-
dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide)] test [51]; MTT is a yellow dye that can be 
absorbed by cells and reduced by mitochondrial dehydrogenases, producing insoluble blue crystals.  
In each well, 10 µl of MTT (5 mg/ml in PBS) were added and plates were put in incubator for 3 or 4 
hours; after incubation, crystals were solubilised adding 100 µl of 0,08 N HCl in isopropanol and 
plates were detected through microplate Bio Rad reader at 570 nm. 
The absorbance of each sample was corrected by instrument which subtracted the mean value of 
blanks (i.e. wells in which there were all the reactives except cells); the absorbance is proportional 
to cellular viability, so the cellular survival was calculated by the following equation: 
 
% CELL SURVIVAL = {[(ASAMPLE – A100%) / A100%] + 1} * 100 
 
where A100% is the mean of controls (i.e. cells without drug nor irradiation exposure, which 
represents 100% of survival) and Asample is the absorbance of various samples in which cells were in 
contact with drug or irradiated in presence of drug. 
For every cellular line, IC50 was measured through Sigma Plot software; IC50 represents the 
compound concentration which leads to death 50% of cell population. 
In phototoxicity experiments, the protective effect of some scavengers was also evaluated. Various 
scavengers were employed: for LCQ compounds N-N’ dimethyl thiourea (DMTU, 1 mM in 
ethanol), 1,4 diazabicyclo[2,2,2]octane (DABCO, 1 mM in PBS) and  2,6-di-tert-
butylhydroxyanisole (BHA, 10 µM in ethanol); for PZQ molecules α-tocopherol (30 µM), sodium 
azide (NaN3, 1 mM in PBS), 1,4 diazabicyclo[2,2,2]octane (DABCO, 1 mM in PBS), reduced 
glutathione (GSH, 1mM in PBS), N-N’ dimethyl thiourea (DMTU, 1 mM in ethanol), mannitol (10 
mM in PBS). Each experiment was repeated at least three times. 
 
 
6.2.7 Colony formation assay 
 
This test was performed with the most active molecules of BQ and PZQ series to confirm their 
cytotoxicity and photocytotoxicity, respectively. 
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In this assay, 7 x 103 cells (A-431 or A-549 cells) were seeded in 2 ml of their proper medium and 
treated with serial concentrations of compounds; for BQ and PZQ treated cells, the growth medium 
was restored after 24 hours treatment and 30 minutes incubation plus 10 minutes irradiation, 
respectively. After a few days and some medium substitutions, cells were stained with crystal violet 
dye and observed with a light microscope; colony formation percentage was then calculated. A 
colony is formed at least by 50 cells. 
 
 
6.2.8 Flow cytometry 
 
Flow cytometry is a very important technique to obtain cellular characteristics: from the presence of 
membrane antigens with immunofluorescence methods to cellular volume, from cellular granularity 
to cellular membrane permeability; with this method we can reveal quantitative and qualitative 
features. 
Flow cytometer is an instrument that makes statistical analysis in samples of microscopic dispersed 
particles in liquid suspension, through light diffusion and fluorescence phenomena. Modern flow 
cytometers are able to analyse several thousand particles every second, in "real time," and can 
actively separate and isolate particles having specified properties. 
 
 
 
Fig. 6.1 Schematic representation of a flow cytofluorimeter. 
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A flow cytometer is similar to a microscope except that, instead of producing an image of the cell, 
flow cytometry offers "high-throughput" (for a large number of cells) automated quantification of 
set parameters. 
Flow cytometer is formed by five components: fluidic system, optical system, electronic system, 
mechanic system and finally data SW-analysis system. 
Fluidic system consists of a flow cell, a special capillary , usually in quartz, where an hydrodynamic 
apparatus permits to obtain the so called “hydrodynamic focalisation”; in this system, single 
particles are forced to flow at the centre of this capillary, where ideally they can perform laminar 
flow. Inside this flow cell, particles are in single line, so the instrument has the possibility to take 
single measures sequentially. The light source can be a laser or mercury vapour lamp. 
The optical system lets the light beam arrive in the capillary core where it is focalised to each single 
cell flowing. Signals from cells are sent to respective photomultipliers; there is also an optical group 
parallel and orthogonal to light beam to check side scattering (SS) and forward scattering (FS), 
respectively. SS gives information about cellular morphology (shape, cytoplasmatic granularity and 
nucleus/cell rate), while FS about the size of objects [52]. In the SS, there are also fluorescent 
phenomena if fluorochromes are utilized for analysis (FITC, PE,etc). The emitted light is checked 
for spectral analysis (separation of wavelength through dichroic spectra) and is sent to 
photomultiplier to amplify signals. Signals are transformed to electric impulses and digitalised; a 
computer analyses the data and helps their visualization. 
The process of collecting data from samples using the flow cytometer is termed “acquisition”, and it 
is mediated by a computer physically connected to the flow cytometer; the software which handles 
the digital interface with the cytometer is capable of adjusting parameters (i.e. voltage, 
compensation, etc.) for the sample being tested, and also assists in displaying initial sample 
information while acquiring sample data to assure that parameters are set correctly. 
Flow cytometry presents numerous advantages: the possibility of multiparametric analysis, the 
reproducibility, the high number of analysed cells (100000 events), the speed of analysis (seconds) 
and the simplicity of the preparation of samples. It is possible to isolate single populations of cell 
(for example living cells) and analyse only in this subpopulation parameters (gating). 
 
6.2.8.1 Determination of the cell death mechanism 
 
In the early stages of apoptosis, some changes occur at the cell surface: one of the first 
modifications is the loss of plasmatic membrane asymmetry, with the translocation of 
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phosphatidylserine (PS) from the inner side of the plasma membrane to the outer layer, by which PS 
becomes exposed at the external surface of the cell. 
Annexin V is a calcium dependent phospholipid-binding protein with high affinity for PS; hence, 
this protein can be used as a sensitive probe for PS exposure upon the cell membrane when 
conjugated with the fluorophore fluorescein isothiocyanate (FITC). 
Translocation of PS to the external cell surface is not unique to apoptosis, but occurs also during 
necrosis; the difference between these two forms of cell death is that during the initial stages of 
apoptosis the cell membrane remains intact, while at the very moment that necrosis occurs the cell 
membrane looses its integrity and becomes leaky. Therefore, the measurement of Annexin V 
binding to the cell surface as indicative for apoptosis has to be performed in conjunction with a dye 
exclusion test to establish integrity of the cell membrane [42]. 
 
 
Fig. 6.2 Annexin V/PI assay. 
 
In these assays, 4 x 105 Jurkat cells were treated with different concentrations of the most cytotoxic 
compounds or irradiated in the presence of the most photocytotoxic molecules; after different times 
of incubation (24 hours, 6 hours or 3 hours), samples were centrifuged and Annexin V-FITC/PI 
solution was added, according to the kit instructions. Samples were incubated for 15 minutes in the 
dark and then were analysed by cytofluorimeter by which the fluorescence of FITC (green, FL1) 
and of PI (red, FL3) were measured. 
In conclusion, living cells do not show any fluorescence, late apoptosis cells demonstrate both 
fluorescence, early apoptotic cells present only the FITC one as their plasmatic membrane is still 
integer, necrotic cells demonstrate PI one. 
 
6.2.8.2 Determination of mitochondrial membrane potential 
 
One parameter of mitochondrial dysfunction is the loss of mitochondrial membrane potential. 
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The mitochondrial membrane potential was measured with the lipophilic cation 5,5’,6,6’ 
tetrachloro-1,1’,3,3’-tetraethylbenzimidazol-carbocyanine (JC-1). 
 
Fig. 6.3 JC-1 dye. 
 
After 6 or 24 hours from the incubation with the most cytotoxic molecules or after 3 or 24 hours 
from the irradiation in the presence of the most photocytotoxic compounds, Jurkat cells were 
collected by centrifugation and resuspended in HBSS containing the JC-1 dye at the concentration 
of 1 µg/ml. Cells were then incubated at 37 °C for 10 minutes, centrifuged and resuspended again in 
HBSS; the cytofluorimetric analysis was performed collecting green (FL1) and orange (FL2) 
fluorescence in at least 10000 events for each sample. 
This method is based on the ability of this fluorescent probe to enter selectively mitochondria and to 
change reversibly its colour from green to orange as membrane potential increases; this property is 
due to the reversible formation of JC-1 aggregates upon membrane polarization that causes shift in 
the emitted light from 530 nm (i.e. emission of JC-1 monomeric form) to 590 nm (emission of J-
aggregate) when excited at 490 nm [53]. 
 
6.2.8.3 Determination of reactive oxygen species (ROS) production 
 
ROS production was evaluated by flow cytometry with two different probes: hydroethidine (HE), 
which reveals superoxide anion, and dihydrochlorofluorescin-diacetate (DCFDA), which reveals 
the presence of hydrogen peroxide [54]. 
In the presence of superoxide anion, hydroethidine is oxidised to ethidium, which intercalates into 
DNA and can give the characteristic red fluorescence. 
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Fig.6.4 Oxidation of hydroethidine to ethidium by superoxide anion. 
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Otherwise, dihydrochlorofluorescin-diacetate penetrates very slowly the cell; then, inside of the 
cell, it is deacetilated by endogenous esterases, so it is trapped in the cytosol. It can be oxidised to 
dichlorofluorescein in the presence of peroxides and can give the characteristic fluorescence in the 
green region. 
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Fig. 6.5 Oxidation of DCHF-DA to DCF by hydrogen peroxide after deacetilation by endogenous esterases. 
 
After 24 hours from the irradiation in the presence of LCQ and PZQ compounds or the treatment 
with BQ molecules, cells were collected by centrifugation and resuspended in HBSS containing the 
fluorescence probes HE or DCFDA at the concentration of 2,5 µM and 5,0 µM respectively. Cells 
were then incubated at 37 °C for 15 or 30 minutes, centrifuged and resuspended again in HBSS. 
The fluorescence was finally recorded with the flow cytometer (Coulter Cytomics FC500) using the 
488 nm wavelength as excitation, and the emission at 620 nm for HE and at 530 nm for DCFDA. At 
least 10000 events for each sample were acquired. 
 
6.2.8.4 Involvement of lysosomes in cell death mechanism 
 
To investigate the integrity of lysosomes, we performed flow cytometric analysis using the 
fluorescent dye acridine orange (AO). 
 
N N N
 
Fig. 6.6 Acridine orange dye (AO). 
 
AO is a lysosomotropic base and a metachromatic fluorochrome exhibiting red fluorescence when 
highly concentrated, as in the case of intact lysosomes where AO is retained in its charged 
protonated form, and green fluorescence at low concentration as in damaged lysosomes. In this 
case, AO relocates to the cytosol where it is predominantly in the deprotonated form [23]. 
After 24 hours from the incubation with BQ derivatives or from the irradiation in the presence of 
LCQ and PZQ compounds, Jurkat cells were collected by centrifugation and resuspended in RPMI 
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containing AO at the concentration of 1 µM; cells were then incubated at 37 °C for 15 minutes, 
centrifuged and resuspended again in RPMI. The fluorescence was directly recorded with the flow 
cytometer (Coulter Cytomics FC500) using the 488 nm wavelength as excitation and the emission 
in FL3 channel. 
 
6.2.8.5 Analysis of cell cycle 
 
The analysis of cell cycle was performed through flow cytometry; this test is based on the fact that 
each cell cycle phase presents a different content of DNA. 
For flow cytometric analysis of DNA content, 5x105 Jurkat cells in exponentially growth were 
treated with different concentrations of compounds; after the incubation period (24 hours), cells 
were centrifuged and fixed with ice-cold ethanol (70%), then treated with PBS buffer containing 
RNAse A (10 Kunit/ml) and propidium iodide (PI, 10 µg/ml). When intercalated in DNA, PI 
fluoresces in the red (620 nm, FL3), if it is excited at 488 nm [52]. Each experiment was repeated 
three times. 
 
Fig. 6.7 Propidium iodide. 
 
Samples were then analysed on a flow cytometer; for cell cycle analysis, results were examined 
with MultiCycle for Windows (Phoenix Flow Systems, San Diego, CA). Data were expressed as 
fractions of cells in the different cycle phases; diagrams of growing cultures display the 
characteristic x-axis distribution according to the DNA content, the first peak corresponding to cells 
in the G1 phase, and the second peak to cells in G2/M phase. Cells with an intermediate DNA 
content are in the S phase. When DNA is fragmented, as in apoptotic cells, the affinity with the 
intercalating PI dye is decreased and a so-called hypodiploid peak (or area) becomes apparent to the 
left of the G1 peak: this is named sub-G1 phase. 
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Fig. 6.8 Representation of cell cycle distribution 
 
 
6.2.9 Evaluation of EGFR inhibition 
 
For protein extraction and western blotting, 106 A-431 cells were seeded in 6 cm Petri dishes; after 
24 hours, they were washed with PBS and starved overnight. Then, cells were incubated with or 
without 20 µM compounds for 3 hours and stimulated with EGF 100 ng/ml for 10 minutes. 
Cell extracts were prepared after scraping in lysis buffer, incubating on ice for 15 minutes and 
clearing by centrifugation; 100 µg of proteins were then loaded in 12,5% SDS-PAGE and then 
blotted to a PVDF membrane (Bio-Rad). Membranes were washed with 0,2% casein, 0,1% Tween-
20 in PBS (blocking buffer) for 1 hour and incubated with polyclonal anti-Phospho-EGFR 
(Tyr1173) (Santa Cruz), anti-Phospho-ERK1/2 (P-p42/p44) (Thr202/Tyr204) (Cell Signaling) 
overnight or with anti-EGFR (Santa Cruz) for 2 hours. After washing in blocking buffer, the 
membranes were incubated with the proper secondary antibody coupled to alkaline phosphatase 
(Jackson immunoresearch laboratories) for 1 hour. 
Visualization was done with CDP-star (Tropix) according to the manufacturer's instructions. 
 
 
6.2.10 Determination of the mitotic index 
 
Exponentially growing Jurkat cells were incubated with test compounds for 24 hours prior to 
centrifugation at 400 rpm  for 5 minutes; the resultant cell pellet was then resuspended in 75 mM 
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KCl solution at 4 °C. After 20 minutes, the fixative methanol-acetic acid (3:l) was slowly added 
under constant mild agitation. 
Slides were prepared after the cells were repelled, washed twice with fixative and resuspended in 
the fixative; after drying, samples were stained with Giemsa solution. 
A total of 400 cells/treatment was scored for the presence of mitotic figures by optical microscopy, 
and the mitotic index was calculated as the proportion of cells with mitotic figures. 
 
 
6.2.11 Evaluation of microtubule network perturbation 
 
Microtubules are dynamic polymers made by the assembly of tubulin, a heterodimer consisting of 
α- and β-tubulin. Microtubule dynamics are involved in many microtubule dependent processes in 
cells, the most important being mitosis. During mitosis, the interphase microtubule network 
completely disassembles and a new assembly of microtubules occurs, leading to the mitotic spindle 
on which the chromosomes attach and segregate to the two spindle poles [47]. 
This feature was evaluated through two tests. 
 
6.2.11.1 Immunofluorescence detection of microtubule perturbation 
 
In this assay, A-431 cells were seeded on sterile microscope coverslips; after 24 hours, 20 µM test 
compounds and 1 µM vinblastine, used as reference compound, were added to the culture medium 
and cells were then incubated for 18 hours. Afterwards, cells were washed twice with PBS and 
treated with cold methanol for 10 minutes at –20 °C; then cell layer was rinsed twice for 10 seconds 
with cold acetone and, after two PBS washes, cells were let rehydrate in PBS for at least 30 
minutes. Later, cells were incubated with monoclonal anti-β-tubulin-FITC antibody diluted in PBS 
containing 1% bovine serum albumin (BSA) for 1 hour at room temperature; slides were then 
washed repeatedly with PBS, mounted with mounting medium, and finally analysed by confocal 
microscopy under green light. 
 
6.2.11.2 Tubulin polymerisation 
 
The effects of test compounds on the polymerisation of microtubule protein isolated from porcine 
brain were analysed by using a microtubule polymerisation assay kit (Cytoskeleton) following the 
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recommended protocol; polymerisation was followed by fluorescent enhancement because of the 
incorporation of a fluorescent reporter into microtubules as polymerisation occurred. 
The assay was performed in 96-well microtiter plates; the reaction was initiated by the addition of 
tubulin. The plate was incubated at 37 °C in a fluorescence microplate reader, and the fluorescence 
measurement (λexcit = 355 nm and λemiss = 450 nm) was determined every minute for 1 hour. 
Vinblastine and Taxol were used as reference compounds. 
 
 
6.2.12 Evaluation of antivascular activity in vitro 
 
6.2.12.1 Motility assay 
 
HUVEC cells (1×105) were seeded into twelve-well plates until a confluent monolayer was formed 
and cell monolayer was scratch wounded using a pipette tip; then, cells were treated with the test 
compounds and, at different times after the scratch, they were photographed under a light 
microscope with 10× magnification. Wound closure was finally evaluated by Optika pro-vision 
software. 
HUVEC cells were purchased from Invitrogen and cultured in 0,3% collagen I-coated flasks in 
M200 medium supplemented with Low Serum Growth Supplement (Invitrogen). 
 
6.2.12.2 Endothelial cell vessel formation on a Matrigel matrix 
 
A Matrigel matrix was kept at 4 °C overnight and then 200 µl of Matrigel were added to each well 
of a 24-well plate. After gelling at 37 °C for 30 min, gels were overlaid with 500 µL of medium 
containing 6 × 104 HUVEC cells; cells were incubated over Matrigel for 6 hours to allow the 
formation of the capillary-like tubes. Then, compounds were added and continuously incubated for 
additional times, and the possible antivascular effect was monitored by optical microscope (at least 
five fields for each well; 10x magnification); pictures were taken using a digital camera and image 
analysis was carried out using the ImageJ image analysis software and evaluating both dimensional 
parameters (percent area covered by cells, total length of cell network per field and percent area 
inside meshes) and topological parameters (number of meshes and branching points per fields). 
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6.2.13 Lipid peroxidation 
 
Lipid peroxidation was monitored by Morlière method or TBARS assay [55], which checks the 
formation of malondialdehyde, one of the final product of this oxidation process, as it reacts with 
thiobarbituric acid. 
250000 Jurkat cells were irradiated (2,5 J/cm2) in the presence of the most active compounds, 
dissolved in HBSS; then, the drug solution was replaced by RPMI medium and cells were incubated 
for 24 hours. 
To verify lipids peroxidation, after cell centrifugation, 900 µl of surnatant were collected and put at 
253 K after having added 90 µl of 2,6-di-tert-butyl-pcresol (BHT, 2% in absolute ethanol). Cells 
were washed, resuspended in 500 µl of water; 400 µl of cells were lysed with 400 µl of SDS (1% in 
water) and vortexed. This suspension was divided into two aliquots: in 500 µl were added 50 µl of 
BHT; 300 µl were used for protein quantification with Peterson method [56]. Lipid peroxidation 
was measured using a thiobarbituric acid assay as described by Morlière et al. [55]. A standard 
curve of 1,1,3,3 tetraethoxypropane was used to quantify the amount of produced malondialdehyde. 
Data were expressed in terms of nanomoles of TBARS normalized to the total protein content in an 
aliquot of the cell extract. 
 
 
 
6.2.14 Photoreaction with model proteins 
 
A possible photoreaction with some model proteins such as BSA and RNAse A was evaluated 
through Balasubramanian method [57]; BSA (Bovine Serum Albumine) is a fluorescent protein 
because of its Trp molecule (λexcit = 280 nm, λemiss = 350 nm), RNAse A because of Tyr residual 
(λexcit = 274 nm, λemiss = 300 nm). 
A 0,5 µM protein solution in phosphate buffer was irradiated with incrementing UVA doses (0, 
1,25, 2,5, 5, 7,5, 11,25 and 15 J/cm2) in the presence of the most active compounds at the 
concentration of 10 µM; to detect the photoreaction, the fluorescence of the solution was observed 
after irradiation: a modification in the solution fluorescence reveals a photoreaction of the 
molecules with the model protein. 
 
 
 
Materials and methods 
________________________________________________________________________________ 
 112
 
 
                                                                                                                                              References 
________________________________________________________________________________ 
 113 
7. References 
 
 
 
 
1. World Health Report, Life in the 21st century. A vision for all., World Health Organisation, 
Geneva, Switzerland (1998). 
 
2. Levi F., Lucchini F., Negri E., Zatonski W., Boyle P., La Vecchia C., Trends in cancer 
mortality in the European Union and accession countries, 1980–2000, Annals of Oncology, 
15 (2004), pp. 1425-1431. 
 
3. Workman P, Kaye S.B., Translating basic cancer research into new cancer therapeutics, 
Trends in Molecular Medicine, 8 (2002), pp. S1-S9. 
 
4. Alberghina L, Gaglio D, Gelfi C., Moresco R.M., Mauri G., Bertolazzi P., Messa C., Gilardi 
M.C., Chiaradonna F., Vanoni M., Cancer cell growth and survival as a system-level 
property sustained by enhanced glycolysis and mithocondrial metabolic remodeling, 
Frontiers in Physiology, 3 (2012), art. 362. 
 
5. Hanahan D., Weinberg R.A., The hallmarks of cancer, Cell, 100 (2000), pp. 57-70. 
 
6. Mitscher L.A., Antibiotics and antimicrobial agents, in “Foye’s principle of medicinal 
chemistry” (2002) Williams D.A., Lemke T.L., ed. Lippincott Williams & Wilkins, pp. 819-
864. 
 
7. Matsumoto Y., Takano H., Fojo T., Cellular adaptation to drug exposure: evolution of the 
drug-resistant phenotype, Cancer Research, 57 (1997), pp. 5086-5092. 
 
8. Davey R.A., Su G.M., Hargrave R.M., Harvie R.M., Baguley B.C., Davey M.W., The 
potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three 
multidrug-resistance phenotypes in vitro, Cancer Chemoter Pharmacol, 39 (1997), pp. 424-
430. 
References 
________________________________________________________________________________ 
 114
9. Dorée M., Galas S, The cyclin-dependent protein kinases and the control of cell division, 
FASEB J., 8 (1994), pp. 1114-1121. 
 
10. Gianni L., Sessa C., Capri G., Grasselli G., Bianchi G., Vitali G., Farmaci chemioterapici in 
Medicina Oncologica, Ed. Masson, Milano (2003), pp. 583-676. 
 
11. Callery P., Gannet P., Cancer and cancer chemotherapy, in “Foye’s principles of medicinal 
chemistry”(2002), D.A. Williams, T.L. Lemke, ed. Lippincott Williams & Wilkins, pp. 924-
951. 
 
12. Middleton M.R., Margison G.P., Improvement of chemotherapy efficacy by inactivation of a 
DNA-repair pathway, Lancet Oncol., 4 (2003), pp. 37-44. 
 
13. Berger J.M., Structure of DNA topoisomerases, Biochim. Biophys. Acta, 1400 (1998), pp. 3-
18. 
 
14. McClendon A.K., Osheroff N., DNA topoisomerase II, genotoxicity, and cancer, Mut. Res., 
623 (2007), pp. 83-97. 
 
15. Galjard N., Perez F., A plus-end raft to control microtubule dynamics and function, Curr. 
Opin. Cell Biol., 15 (2003), pp. 48-53. 
 
16. Jordan A., Hadfield J.A., Lawrence N.J., McGown A.T., Tubulin as a target for anticancer 
drugs: agents which interact with the mitotic spindle, Inc. Med. Res. Rev., 18 (1998), pp. 
259-296. 
 
17. Zhou J., Giannakakou P., Targeting microtubules for cancer chemotherapy, Curr. Med. 
Chem – Anti-Cancer Agents, 5 (2005), pp. 65-71. 
 
18. Sawyers C., Targeted cancer therapy, Nature, 432 (2004), pp. 294-297. 
 
19. Cohen P., Protein kinases- the major drug target of the twenty-first century?, Nat. Rev., 1 
(2002), pp. 309-316. 
 
                                                                                                                                              References 
________________________________________________________________________________ 
 115 
20. Ziegler U., Groscurth P., Morphological features of cell death, News Physiol. Sci., 19 
(2004), pp. 124-128. 
 
21. Wang X., The expanding role of mitochondria in apoptosis, Genes and Development, 15 
(2001), pp. 2922-2933. 
 
22. Ricci J.E., Gottlieb R.A., Green D.R., Caspase-mediate loss of mitochondrial function and 
generation of reactive oxygen species during apoptosis, J. Cell Biol, 1 (2003), pp. 65-75. 
 
23. Zhao M., Eaton J.W., Brunk U.T, Protection against oxidant-mediated lysosomal rupture: a 
new anti-apoptotic activity of Bcl-2?, FEBS Lett., 485 (2000), pp. 104-108. 
 
24. Parrish J.A., Fitzpatrick T.B., Pathak M.A., Tanenbaum L., Photochemotherapy of psoriasis 
with oral methoxsalen and longwave ultraviolet light, N. Engl. J. Med., 291 (1974), pp. 
1207-1211. 
 
25. Walker D., Jacobe H., Phototherapy in the age of biologics, (2011), pp. 190-198. 
 
26. Teiten M.H., Bezdetnaja L., Merlin J.L., Bour-Dill C., Pauly M.E., Dicato M, Guillemin F., 
Effect of meta-tetra(hydroxyphenyl)chlorin (mTHPC)-mediated photodynamic therapy on 
sensitive and multidrug-resistant human breast cancer cells, J. Photochem. Photobiol., 62 
(2001), pp. 146-152. 
 
27. Dolmans D.E.J.G.J., Fukumura D., Jain R.K., Photodynamic therapy for cancer, Nature, 
vol. 3 (2003), pp. 380-387. 
 
28. Dalla Via L., Marciani Magno S., Rodighero P., Gia O., Synthesis, photobiological activity 
and photoreactivity of methyl-thieno-8-azacoumarins, novel bioisosters of psoralens, 
Bioorg. Medicin. Chem. Lett., 12 (2002), pp. 1253-1257. 
 
29. Bethea D., Fullmer B., Syed S., Seltzer G., Tiano J., Rischko C., Gillespie L., Brown D., 
Gasparro F.P., Psoralen photobiology and photochemotherapy: 50 years of science and 
medicine, J. Dermatol. Sci., 19 (1999), pp. 78-88. 
 
References 
________________________________________________________________________________ 
 116
30. Bartošová J., Kuželová K., Pluskalová M., Marinov I., Halada P., Gašová Z., UVA-activated 
8-methoxypsoralen (PUVA) causes G2/M cell cycle arrest in Karpas 299 T-lymphoma cells, 
J. Photochem. Photobiol., 85 (2006), pp. 39-48. 
 
31. Bladon J, Taylor P.C., Extracorporeal photopheresis: a focus on apoptosis and cytokines, J. 
Dermatol. Sci., 43 (2006), pp. 85-94. 
 
32. Marzano C., Chilin A., Bordin F., Baccichetti F., Guiotto A., DNA damage and biological 
effects induced by photosensitization with new N1-unsubstituted furo[2,3-h]quinolin-2(1H)-
ones, Bioorg. Medicin. Chem. Lett., 10 (2002), pp. 2835-2844. 
 
33. Hennequin L.F., Thomas A.P., Johnstone C., Stokes E.S.E., Plé P.A., Lohman J.M., Ogilvie 
D.J., Dukes M., Wedge S.R., Curwen J.O., Kendrew J., Lamber-van der Brempt C., Design 
and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase 
inhibitors, J. Med. Chem., 42 (1999), pp. 5369-5389. 
 
34. Palmer B.D., Trumpp-Kallmeyer S., Fry D.W., Nelson J.M., Showalter H.D.H., Denny 
W.A., Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and 
pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological 
evaluation, and modeling of the mode of binding, J. Med. Chem., 40 (1997), pp. 1519-1529. 
 
35. Matsuno K., Nakajima T., Ichimura M., Giese N.A., Yu J., Lokker N.A., Ushiki J., Ide S., 
Oda S., Nomoto Y., Potent and selective inhibitors of PDGF receptor phosphorilation. 2. 
Synthesis, structure activity relationship, improvement of aqueous solubility, and biological 
effect of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline 
derivatives, J. Med. Chem., 45 (2002), pp. 4513-4523. 
 
36. Hunt J.T., Mitt T., Borzilleri R., Gullo-Brown J., Fargnoli J., Fink B., Han W., Mortillo S., 
Vite G., Wautlet B., Wong T., Yu C., Zheng X., Bhide R., Discovery of the pyrrolo[2,1-
f][1,2,4]triazine nucleus as new kinase inhibitor template, J. Med. Chem., 47 (2004), pp. 
4054-4059. 
 
 
                                                                                                                                              References 
________________________________________________________________________________ 
 117 
37. Wolf P., Nghiem D.X., Walterscheid J.P., Byrne S., Matsumura Y., Matsumura Y., Bucana 
C., Ananthaswamy H.N., Ullrich S.E., Platelet-Activating Factor Is Crucial in Psoralen and 
Ultraviolet A-Induced Immune Suppression, Inflammation, and Apoptosis, Am. J. Phatol., 3 
(2006), pp. 795-805. 
 
38. Song P.S., Tapley K.J., Photochemistry and photobiology of psoralens, Photochem. 
Photobiol., 29 (1979), pp. 1177-1197. 
 
39. Moyer J.D., Barbacci E.G., Iwata K.K., Arnold L., Broman B., Cunningham A., Di Orio C., 
Doty J., Morin M.J., Moyer M.P., Neveu M., Pollack V.A., Pustilnik L.R., Reynolds M.M., 
Sloan D., Theleman A., Miller P., Induction of apoptosis and cell cycle arrest by CP-
358,774, an inhibitor of Epidermal Growth Factor Receptor Tyrosin Kinase, Cancer Res., 
57 (1997), pp. 4838-4848. 
 
40. Wedge S.R., Ogilvie D.J., Dukes M., Kendrew J., Curwen J.O., Hennequin L.F., Thomas 
A.P., Sokes E.S.E., Curry B., Richmond G.H.P., Wadsworth P.F., ZD4190: An orally active 
inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor 
efficacy, Cancer Res., 60 (2000), pp. 970-975. 
 
41. Hennequin L.F., Stokes E.S.E., Thomas A.P., Johnstone C., Plé P.A., Ogilvie D.J., Dukes 
M., Wedge S.R., Kendrew J., Curwen J.O., Novel 4-anilinoquinazolines with C-7 basic side 
chains: design and structure activity relationship of a series of potent, orally active, VEGF 
receptor tyrosine kinase inhibitors, J. Med. Chem., 45 (2002), pp. 1300-1312. 
 
42. Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C., A novel assay for 
apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic 
cells using fluorescein labelled Annexin V, J. Immun. Methods, 184 (1995), pp. 39-51. 
 
43. Kroemer G., Zamzani N., Susin S.A., Mitochondrial control of apoptosis, Immunol. Today, 
18 (1997), pp. 44-51. 
 
44. Cossarizza A., Baccarani Contri M., Kalashnikova G., Franceschi C., A new method for the 
cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate 
References 
________________________________________________________________________________ 
 118
forming lipophilic cation 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolcarbocyanine 
iodide (JC-1), Biochem. Biophys Res. Commun., 197 (1993), pp. 40-45. 
 
45. Reers M., Smith T.W., Chen L.B., J-aggregate formation of a carbocyanine as a 
quantitative fluorescent indicator of membrane potential, Biochemistry, 30 (1991), pp. 
4480-4486. 
 
46. Andreyev A.Y., Kushnareva Y.E., Starkov A.A., Mitochondrial metabolism of reactive 
oxygen species, Biochemistry (Mosc.), 70 (2005), pp. 200-214. 
 
47. Zhai Y., Kronebusch P.J., Simon P.M., Borisy G.G., Microtubule dynamics at the G2/M 
transition: Abrupt breakdown of cytoplasmic microtubules at nuclear envelope breakdown 
and implications for spindle morphogenesis, J. Cell. Biol., 135 (1996), pp. 201–214. 
 
48. Staton C.A., Reed M.W.R., Brown N.J., A critical analysis of current in vitro and in vivo 
angiogenesis assays, Int. J Exp. Path., 90 (2009), pp. 195-221. 
 
49. Caffieri S., Furocoumarin photolysis: chemical and biological aspects, Photochem. 
Photobiol. Sci., 1 (2002), pp. 149-157. 
 
50. Santini M.T., Romano R., Rainaldi G., Filippini P., Bravo E., Porcu L., Motta A., Calcabrini 
A., Mescini S., Indovina P.L., Arancia G., The relationship between 1H-NMR mobile lipid 
intensity and cholesterol in two human multidrug resistant cell lines (MCF-7 and LoVo), 
Biochim. Biophys. Acta, 1531 (2001), pp. 111-131. 
 
51. Mosmann T., Rapid colorimetric assay for cellular growth and survival: application to 
proliferation and citotoxic assay, J. Immunol. Meth., 65 (1983), pp. 55-63. 
 
52. Darzynkiewicz Z., Juan G., Li X., Gorczyca W., Muratami T., Traganos F., Cytometry in 
cell necrobiology: analysis of apoptosis and accidental cell death (necrosis), Cytometry, 21 
(1997), pp. 1-20. 
 
53. Salvioli S., Ardizzoni A., Franceschi C., Cossarizza A., JC-1 but not DiOC6(3) or 
rhodamine 123 is a reliable fluorescent probe to asses Ψ∆ changes in intact cells: 
                                                                                                                                              References 
________________________________________________________________________________ 
 119 
implications for studies on mitochondrial functionality during apoptosis, FEBS Lett., 411 
(1997), pp. 77-82. 
 
54. Rothe G., Valet G., Flow cytometric analysis of respiratory burst activity in phagocytes with 
hydroethidine and 2',7'-dichlorofluorescin, J. Leukoc. Biol., 47 (1990), pp. 440-448. 
 
55. Morlière P., Moysan A., Santus R., Hüppe G., Mazière J., Dubertret L., UVA-induced lipid 
peroxidation in cultured human fibroblasts, Biochem. Biophys. Acta, 1084, (1991), pp. 261-
268. 
 
56. Peterson G.L., A simplification of the protein assay method of Lowry et al. which is more 
generally applicable, An. Biochem., 83 (1977), pp. 346-356. 
 
57. Balasubramanian D., Du X., Zigler J.S., The reaction of singlet oxygen with proteins, with 
special reference to crystalline, Photochem. and photobiol., 52 (1990), pp. 761-776. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
________________________________________________________________________________ 
 120
 
  121 
UNIVERSITA’ DEGLI STUDI DI PADOVA, DIPARTIMENTO DI SCIENZE DEL FARMACO 
Professoressa Daniela Vedaldi, Professor Francesco Dall’Acqua, Dottoressa Alessia Salvador, Alice 
Ballan. 
 
 
UNIVERSITA’ DEGLI STUDI DI PADOVA, DIPARTIMENTO DI BIOLOGIA 
Professoressa Luisa Dalla Valle. 
 
 
UNIVERSITA’ DEGLI STUDI DI PADOVA, DIPARTIMENTO DI MEDICINA MOLECOLARE 
Professor Ignazio Castagliuolo, Dottoressa Paola Brun. 
 
 
UNIVERSITA’ DEGLI STUDI DI PALERMO, DIPARTIMENTO FARMACOCHIMICO, 
TOSSICOLOGICO E BIOLOGICO 
Professor Girolamo Cirrincione, Assistant Professor Patrizia Diana, Assistant Professor Paola 
Barraja. 
